Peter F. Thall

Department of Biostatistics, Division of Discovery Science

About Peter F. Thall

Peter F. Thall is the Anise J. Sorrell Professor in the Department of Biostatistics at M.D. Anderson Cancer Center, where he has been a Science Faculty member since 1990. He is a Fellow of the American Statistical Association (ASA) and the Society for Clinical Trials, and received the Owen Award in 2014. Dr. Thall has pioneered the application of Bayesian methods in medical research. He is an author of over 260 papers and book chapters in the statistical and medical literature, co-authored the 2016 Chapman & Hall book "Bayesian Designs for Phase I-II Clinical Trials" and authored the 2020 Springer book ‘Statistical Remedies for Medical Researchers.’ He has designed hundreds of clinical trials in numerous areas of oncology. He has presented over 230 invited talks, and 34 short courses, served as an Associate Editor for J. National Cancer Institute, Statistics in Medicine, Statistics in Biosciences, Clinical Trials, and Biometrics, and is an ASA Media Expert.

Click to view personal webpage

Primary Appointment

Endowed Professorship Anise J. Sorrell Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Anise J. Sorrell Professor, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Bayesian statistics

Clinical trial design

Medical decision analysis

Personalized medicine

Dynamic treatment regimes

Education & Training

Degree-Granting Education

1975	Florida State University, Tallahassee, Florida, US, Statistics & Probability, Ph.D
1973	Florida State University, Tallahassee, Florida, US, Statistics, M.S
1971	Michigan State University, East Lansing, Michigan, US, Mathematics, BS

Experience & Service

Faculty Academic Appointments

Adjunct Professor, Department of Statistics, Rice University, Houston, TX, 2013 - 2023

Adjunct Member of the Graduate Faculty, Texas A&M University, Houston, TX, 2007 - 2012

Professor, Dept of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX, 2000 - 2006

Professor, Dept of Biomathematics, M.D. Anderson Cancer Center, Houston, TX, 1998 - 2000

Associate Professor, Dept of Biomathematics, M.D. Anderson Cancer Center, Houston, TX, 1991 - 1998

Special Assistant to the Chief, Division of Cancer Treatment,, Biometric Research Branch, CTEP, DCT, NCI, Bethesda, MD, 1986 - 1987

Associate Professor, Dept of Statistics, George Washington University, Washington, DC, 1984 - 1990

Statistician, National Cooperative to Gallstone Study, Biostatistics Center, George Washington University, Washington, DC, 1982 - 1983

Assistant Professor, Dept of Statistics, George Washington University, Washington, DC, 1980 - 1984

Assistant Professor, Program in Mathematical Sciences, University of Texas at Dallas, Richardson, TX, 1975 - 1980

Biometry Intern, Department of Statistics, Oak Ridge National Laboratory, Oak Ridge, TN, 1973 - 1973

Administrative Appointments/Responsibilities

Biostatistician, Translational Molecular Pathology Clinical Research Group, Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Biostatistician, Protocol PA13-0786, Z. Liao, PI, Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019

Biostatistician, Nanobiotix Strategic Alliance, Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019

Other Professional Positions

External Grant Proposal Reviewer, Molecular and Cellular Sciences and Technologies Review Branch, NIH, Center for Scientific Review, Bethesda, MD, 2025 - 2025

Biostatistical Reviewer, NIH NINDS ZNS1 SRB A(09) Special Emphasis Panel, NINDS Efficacy Clinical Trials program PAR-21-237, Bethesda, MD, 2024 - 2024

Biostatistical Reviewer, NIH NINDS ZNS1 SRB A(09) Special Emphasis Panel, Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology RFA-NS-24-013;, NINDS Efficacy Clinical Trials program, Bethesda, MD, 2024

Data and Safety Monitoring Board, SMART-JIA trial, PI Laura Schanberg PI, Dual PI Huiman Barnhart, International PI Fabrizio De Benedett, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, 2024 - 2025

Member, Stakeholder Advisory Board, Pragmatic Comparative Effectiveness using SMARTs, Patient Centered Outcomes Research Institute (PCORI), Wahed,PI, 2023 - 2025

Member, Review Panel, FDA Center for Drug Evaluation and Research, Workshop on Efficient Evaluation of Biosimilar Products, Bethesda, Maryland, 2022

Member, Editorial Board for a special issue of Clinical Trials on modern dose-finding designs, Houston, TX, 2022 - 2023

Scientific Advisory Board, Cellenkos RESOLVE Trial of Cryopreserved Cord Blood Derived T-Regulatory Cells in the Treatment of COVID-19 Induced Acute Respiratory Distress Syndrome, Houston, TX, 2022

Biostatistical Reviewer, NIH NINDS Special Emphasis Panel ZNS1 SRB-A(47), Early Phase Clinical Trial Network EPPIC-NET, Bethesda, Maryland, 2021

Biostatistical Reviewer, NINDS NHLBI, SIREN Emergency Clinical Trial Network, Bethesda, Maryland, 2019

Member, NINDS Preclinical Assessment Network Special Emphasis Panel/Scientific Review Group 2019/05 ZNS1 SRB-D, Bethesda, Maryland, 2019

Visiting Research Scientist, INSERM, Data Science and Personalized Medicine, French National Institute for Health and Medical Research, Paris, France, 2016

Statistical Consultant, AstraZeneca, Boston, MA, 2016

Member, Regional Advisory Board, ENAR, International Biometric Society, Alexandria, Virginia, 2013 - 2015

Statistical Consultant, Cytel Corporation, Cambridge, MA, 2012 - 2014

Program Chair 2013, Section on Bayesian Statistical Sciences, American Statistical Association, Alexandria, VA, 2011 - 2012

Member, Androgen Receptor Signaling in Prostate Cancer: Translating Biology into Clinical Practice. Prostate Cancer Task Force, Genitourinary Steering Committee, 2010

Member, Data Safety Monitoring Board, “Multi-institutional Trial of Allogeneic Bone Marrow Transplantation for Hematologic Malignancies using HLA-matched Related or Unrelated Donors with Fludarabine and IV Busulfan as Pre-transplant Conditioning followed by Post-, 2010 - 2012

Statistical Consultant, Takeda Oncology Company, Boston, MA, 2010

Member, AML Working Group, Lymphoma Steering Committee, National Cancer Institute, Bethesda, MD, 2010

Statistical Consultant, Fertility Center of Las Vegas, Las Vegas, NV, 2009

Member, Special Emphasis Panel/Scientific Review Group 2010/01 ZHL1 CSR-D (F1), National Heart, Lung, and Blood Institute, RFA-HL-10-007: Prematurity and Respiratory Outcomes Program, Bethesda, MD, 2009

Media Expert, American Statistical Association, Alexandria, VA, 2008 - 2023

Statistical Consultant, Guidepoint Global, New York, NY, 2008 - 2010

Member, Data Safety Monitoring Board, "A Phase II Trial of IT-101 for Advanced Ovarian Cancer," Calando Pharmaceuticals, Pasadena, CA, 2008 - 2009

Statistical Consultant, Hoffman-LaRoche, Nutley, NJ, 2008

Statistical Consultation and Advice, Scian Services, Toronto, ON, Canada, 2006

Member, External Advisory Board, Head and Neck Cancer SPORE, Winship Cancer Institute, Emory University, D. Shin, PI, F. Khuri, Co-PI, Atlanta, GA, 2006

Member, External Advisory Board, Epithelial Ovarian Cancer Program Project Grant, Memorial Sloan-Kettering Cancer Center, Houston, TX, 2005 - 2011

Statistical Consultant, Chiron Corporation, Emeryville, CA, 2005

Statistical Consultant, Applied Molecular Evolution, San Diego, CA, 2004

Statistical Consultation and Advice, ESP Pharmaceuticals, Edison, NJ, 2004

Head Statistician, Sarcoma Alliance for Research Through Collaboration (SARC), Arbor, Michigan, 2003 - 2007

Member, Liposomal Topotecan Advisory Board, GlaxoSmithKline, n/a, 2003

Co-Chair, "Better Clinical Studies", Science--Centric Session, NCI, Sarcoma Progress Review Group, Philadelphia, PA, 2003

Member, Data Safety Monitoring Board, ReoPro Retavase Reperfusion of Stroke Safety Study - Imaging Evaluation, NINDS, S. Warach, P.I, Rockville, MD, 2002 - 2007

Member, Data Safety Monitoring Board, "An Adaptively Randomized Trial of Gemcitabine 1200 mg/m2 versus Gemcitabine 900 mg/m2 + Docetaxel for Unresectable Soft Tissue Sarcoma", Connective Tissue Oncology Society, R. Maki, P.I, New York, New York, 2002 - 2005

Member, External Advisory Committee, "Growth Control in Multiple Myeloma", Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, Little Rock, AR, 2000 - 2006

Visiting Lecturer, Dept of Applied Statistics, University of Reading, Dept of Applied Statistics, University of Reading, Reading, 1997

Statistical Consultant, Novartis Pharmaceuticals, Basel, Switzerland and Morristown, NJ, 1996 - 2004

Statistical Consultation and Advice, Logistics Management Institute, Bethesda, MD, 1989

Statistical Consultation and Advice, Georgetown University School of Nursing, Washington, 1984

Extramural Institutional Committee Activities

Biostatistical Reviewer, Multidisciplinary Research Project Grant Application, The University of Texas MD Anderson Cancer Center, 2021

Leading Clinical Research Faculty Learning Series, Small Group Session Biostatistics Expert, The University of Texas MD Anderson Cancer Center, 2021

Biostatistician, Provided mentoring in clinical trial design and protocol development for Drs. D. Mitra, A. Livingston, P. Fang, T. Beckham, and J. Tu, Translational Molecular Pathology Clinical Research Group, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2020 - Present

Biostatistician, Nanobiotix Strategic Alliance, Dept of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2019 - Present

Biostatistician, Protocol PA-13-0786, Zhongxing Liao, PI, Dept of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Mid-Tenure Review Committee for D. Fuentes, The University of Texas MD Anderson Cancer Center, 2016

Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2017

Chair, Mid-Tenure Review Committee for Bryan Hobbs, Ph.D, The University of Texas MD Anderson Cancer Center, 2014

Reviewer, MDACC Research Administration, Start Up Funds Proposal, The University of Texas MD Anderson Cancer Center, 2013

Member, Mid-Tenure Review Committee for M. Guindani, The University of Texas MD Anderson Cancer Center, 2013

Biostatistics Department, Statistical Computing Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2014

Chair, Mid-Tenure Review Committee for Guosheng Yin, Ph.D, The University of Texas MD Anderson Cancer Center, 2006

Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2007

Member, Study Section Review Committee for Clinical, Translational and Population-based Projects, Institutional Research Grants Program, The University of Texas MD Anderson Cancer Center, 2002 - 2008

Member, Institutional Research Grants Program, The University of Texas MD Anderson Cancer Center, 2002 - 2008

Chair, Biostatistics Department Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Member, Faculty Performance Evaluation System Survey Focus Group, The University of Texas MD Anderson Cancer Center, 1999

Member, Achievement Award Subcommittee, Clinical Research Category, The University of Texas MD Anderson Cancer Center, 1998

Chairman, Mid-Tenure Review Committee for J. Jack Lee, Ph.D, The University of Texas MD Anderson Cancer Center, 1995

Member, Institutional Research Support Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1997

Director, Clinical Biostatistics Center, Search Committee for Chief, Section of Biostatistics, The University of Texas MD Anderson Cancer Center, 1993 - 1994

Editorial Activities

Associate Editor, Special Issue of Clinical Trials on Dose-Finding Trials, 2022 - 2024

Associate Editor, Biometrics, 2017 - 2021

Associate Editor, Statistics in Biosciences, 2008 - 2018

Associate Editor, Clinical Trials, 2003 - Present

Associate Editor, Biometrics, 2003 - 2008

Associate Editor, Journal of the National Cancer Institute, 1995 - 1997

Associate Editor, Statistics in Medicine, 1994 - 2005

Honors & Awards

2024 - Present	Paper chosen for the Wall of Science at MD Anderson: Nature Medicine 2024, Safety, efficacy and determinants of response of Allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial’
2022 - 2023	One of the 10 most cited papers published in Pharmaceutical Statistics during 2022-2023, Generalized phase I-II designs to increase long term therapeutic success rate
2021	Paper chosen for the Wall of Science at MD Anderson: J Clinical Oncology, 2021, ‘Third-party BK virus specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation’
2020	Awarded best paper published in Biometrics in 2019, Chapple and Thall Biometrics 85, 371-381, 2019
2020	Awarded best paper published in Biometrics in 2019: Chapple and Thall, Biometrics 85, 371-381, 2019
2019 - Present	Editors’ award for the best paper published in Biometrics in 2019, A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III
2015	Fellow, American Statistical Association
2014	Fellow, Society for Clinical Trials
2014	Owen Award, San Antonio Chapter of the American Statistical Association
1971	All University Competitive Fellow, Flordia State University

Professional Memberships

International Society for Bayesian Analysis

2020 - 2025

The International Biometric Society

1988 - 2025

Society for Clinical Trials

1985 - 2024

American Statistical Association

1971 - 2024

Selected Presentations & Talks

Local Presentations

2022. Fatal Statistical Practices in Medical Research: The Emperor Has No Clothes. Invited. Department of Biostatistics, University of Michigan, US.
2022. Discussion, in the session “Bayesian Integration of Data Sources to Inform the Stepwise Approach and Comparative Clinical Study". Invited. Center for Drug Evaluation and Research, US FDA Public Workshop, “Increasing the Efficiency of Biosimilar Development Programs”, US.
2020. Invited ‘fireside chat’ with the graduate students in the Department of Biostatistics. Invited. Harvard University, done virtually October 26, 2020, US.
2020. A New Hybrid Phase I-II-III Clinical Trial Paradigm. Department of Data Sciences. Invited. Frontiers in Biostatistics Seminar, Dana-Farber Cancer Institute. Originally scheduled for June 2, 2020 but delayed due to COVID-19 pandemic, re-scheduled for virtual presentation September 15, 2020, US.
2019. Survival Analysis and Some Statistical Graphics. Invited. Department of Endocrine Neoplasia and Hormonal Disorders. Houston, TX, US.
2019. Randomization and Bias in Clinical Research: Basic Concepts and Some Recent Trial Designs. Invited. Department of Endocrine Neoplasia and Hormonal Disorders. Houston, TX, US.
2019. Two Utility-Based Bayesian Designs with Adaptive Subgroup-Specific Decisions for Precision Medicine. Invited. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center. Houston, TX, US.
2019. Statistical Remedies for Flawed Conventions in Medical Research. Invited. School of Public Health, Louisiana State University, LA, US.
2018. Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer. Invited. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center. Houston, TX, US.
2018. Dysfunctional Conventions in Clinical Trials: Some Practical Alternatives. Invited. MD Anderson Cancer Center. Houston, TX, US.
2018. Randomization and Bias in Clinical Research: Basic Concepts and Some Recent Trial Designs. Invited. MD Anderson Cancer Center. Houston, TX, US.
2016. Randomization and Bias in Clinical Research: Basic Concepts and Two Recent Applications. Invited. MD Anderson Cancer Center. Houston, TX, US.
2016. Caveats for Outcome Adaptive Randomization in Comparative Clinical Trials. Systemes d'Information et Medecine Personnalisee. Invited. Centre de Recherche des Cordeliers, INSERM. Paris, FR.
2016. Dysfunctional Conventions in Cancer Clinical Trials: Some Practical Alternatives. Conference. MD Anderson Cancer Center. Houston, TX, US.
2016. Dysfunctional Conventions in Clinical Trials: Some Practical Alternatives. Early Phase Biometrics. Invited. AstraZeneca Pharmaceuticals. Boston, MA, US.
2015. Interim Analyses of Data from START Trial Protocol 2010-0085 (N. Tannir, PI). Conference. MD Anderson Cancer Center. Houston, TX, US.
2015. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2015. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. University of Texas Southwestern Medical Center. Dallas, TX, US.
2015. SMART Design, Conduct and Analysis in Oncology. Invited. Centre de Recherch des Cordeliers, INSERM. Paris, FR.
2015. Dysfunctional Conventions in Cancer Clinical Trials, and Some Practical Alternatives. Conference. MD Anderson Cancer Center. Houston, TX, US.
2014. Bayesian Methods for Targeted Agents in Early Phase Clinical Trials. Invited. INSERM UMRS 1138, Information Sciences t support Personalized Medicine, Centre de Recherche des Cordeliers. Paris, FR.
2014. Bayesian Utility-Based Designs. Dynamic Treatment Regimes and Personalized Medicine. Conference. MD Anderson Cancer Center. Houston, TX, US.
2014. Counterintuitive Properties of Clinical Trials: Bayesian Methods to Avoid Getting it Wrong. Conference. MD Anderson Cancer Center. Houston, TX, US.
2013. Dysfunctional Conventions in Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2013. Bayesian Hybrid Adaptive Designs for Clinical Trials. Invited. Cancer Outcomes Research Program and Sheps Center for Health Services Research, University of North Carolina, NC, US.
2013. Dysfunctional Conventions in Clinical Trials: Some Practical Alternatives. Conference. MD Anderson Cancer Center. Houston, TX, US.
2013. 23 Years Working as a Biostatistician at M D Anderson Cancer Center: Some Very Brief Examples. Conference. Rice University/ MD Anderson Cancer Center. Houston, TX, US.
2013. Innovative Bayesian Methods for Early Phase Clinical Trials. Conference. Graduate School of Biomedical Sciences, MD Anderson Cancer Center. Houston, TX, US.
2013. Dysfunctional Conventions in Clinical Trials: Some Practical Alternatives. Conference. MD Anderson Cancer Center. Houston, TX, US.
2012. A Bayesian Adaptive Design to Optimize Sedative Dose for Neonates Prior to Intubation. Invited. Hôpital Universitaire des Enfants Reine Fabiola. Brussels, BE.
2012. Utility-Based Methods for Early Phase Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2012. 22 Years Working as a Biostatistician in a Cancer Center: A Few Snapshots. Conference. Presentation to the Rice University Summer Institute of Statistics students. Houston, TX, US.
2012. Evaluating Induction-Salvage Treatment Regimes in Therapy of AML/MDS. Conference. MD Anderson Cancer Center. Houston, TX, US.
2011. Navigating the Rocky Shoals of Adaptive Clinical Trial Design and Conduct. Invited. Biosatistiques et Epidémiologie Clinique. Saint - Louis, FR.
2010. New Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. Tufts University School of Medicine. Boston, MA, US.
2010. Patient-Specific Dose-Finding Based On Bivariate (Efficacy, Toxicity) Outcomes and Covariates. Invited. University of Tokyo. Tokyo, JP.
2010. A Bayesian-Frequentist Geometric Phase II-III Select-and-Test Design: Evaluating Chemotherapies for Choroid Plexus Carcinomas in Children. Conference. MD Anderson Cancer Center. Houston, TX, US.
2010. A Bayesian-Frequentist Geometric Phase II-III Select-and-Test Design: Evaluating Chemotherapies for Choroid Plexus Carcinomas in Children. Conference. MD Anderson Cancer Center. Houston, TX, US.
2009. Monitoring Multiple Events in Early Phase Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2009. Innovative Bayesian Adaptive Clinical Trial Designs. Conference. MD Anderson Cancer Center. Houston, TX, US.
2009. Innovative Bayesian Methods for Early Phase Clinical Trials. Conference. Graduate School of Biomedical Sciences, MD Anderson Cancer Center. Houston, TX, US.
2009. Bayesian Designs for Clinical Trials with Dynamic Re-Randomization. Invited. Biostatistics Workshop in Cancer Research, University of Toronto, Dalla Lana School of Public Health. Toronto, CA.
2009. Two Adaptive Bayesian Designs for Early Phase Clinical Trials. Conference. Presented to External Review Panel for the Division of Quantitative Sciences at MD Anderson Cancer Center. Houston, TX, US.
2008. Adaptive Randomization in Clinical Trials,. Conference. MD Anderson Cancer Center. Houston, TX, US.
2008. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times. Invited. Institut Bergonie. Bordeaux, FR.
2008. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times. Invited. University of Pittsburgh, Department of Statistics. Pittsburgh, PA, US.
2008. Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent: A New Paradigm for Phase I Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2008. Accounting for Patient Heterogeneity and Multivariate Outcomes in Early Phase Clinical Trials. In the session "Bayesian Treatment of Multiplicities in Clinical Trials". Conference. MD Anderson Cancer Center. Houston, TX, US.
2007. Some New Bayesian Designs for Early Phase Clinical Trials. Invited. City of Hope Cancer Center. Duarte, CA, US.
2007. Adaptive Randomization in Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2006. Covariate-Adjusted Adaptive Randomization in a Clinical Trial with Multi-stage Therapy. Invited. Division of Cancer Treatment & Diagnosis, National Cancer Institute. Rockville, MD, US.
2006. Adaptive Randomization in Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2005. (i) Dose Finding Based on Efficacy and Toxicity in Phase I/II Clinical Trials and (ii) Some Designs for Combining Phase II and Phase III Clinical Trials. Invited. CRLC Val d'Aurelle. Montpellier, FR.
2004. Some Bayesian Adaptive Methods for Clinical Trial Design and Conduct. Invited. Pharsight Drug Development Consulting Services. Cary, NC, US.
2003. (i) Covariate-Adjusted Adaptive Randomization in a Sarcoma Trial With Multi-Stage Treatments and (ii) New Methods for Dose-Finding in Early Phase Clinical Trials. Invited. School of Public Health. Ann Arbor, MI, US.
2003. New Methods for Dose-Finding in Early Phase Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2003. Adaptive Decision-Making in Cancer Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2003. Effects of Tacrolimus Level on Survival Time in Allogeneic Transplant Patients. Conference. MD Anderson Cancer Center. Houston, TX, US.
2003. Dose-Finding in Early Phase Clinical Trial. Conference. MD Anderson Cancer Center. Houston, TX, US.
2003. Dose-Finding in Early Phase Clinical Trials I: Methods Based on Toxicity. Conference. MD Anderson Cancer Center. Houston, TX, US.
2003. Adaptive Designs for Multi-Course Therapies. Conference. MD Anderson Cancer Center. Houston, TX, US.
2003. Practical Adaptive Decision-Making in Oncology Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2002. Dose-Finding with Two Agents in Phase I Oncology Trials. Invited. Columbia University. New York, NY, US.
2002. A General Approach to a Two-Component Phase I Trial, (presented jointly with R. Millikan). Conference. MD Anderson Cancer Center. Houston, TX, US.
2002. Adaptive Designs for Early Phase Oncology Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
2002. Recent Advances in Outcome-Adaptive Clinical Trial Design. Conference. Department of Genitourinary Oncology. Houston, TX, US.
2001. A Survival Analysis of Data from 90 Chronic Lymphocytic Leukemia patients treated at MDACC. Conference. MD Anderson Cancer Center. Houston, TX, US.
2001. Dose-Finding Based on Response and Toxicity: The Phase I/II Design. Invited. National Institute of Neurological Disorders and Stroke, NIH. Rockville, MD, US.
2001. A New Statistical Strategy for Evaluating AML/MDS Treatment Strategies. Conference. MD Anderson Cancer Center. Houston, TX, US.
2001. (i) Bayesian Methods for Early Phase Clinical Trials: Dose-Finding and Safety Monitoring; and (ii) Adaptive Designs: A Non-Small Cell Lung Cancer Trial. Conference. MD Anderson Cancer Center. Houston, TX, US.
2000. Bayesian Strategies for Small n Clinical Trials. Invited. Conference on Future Directions for Small n Clinical Research Trials. Washington, DC, US.
2000. Evaluating Multiple Treatment Courses in Clinical Trials. Invited. The Abbott Laboratories Distinguished Lectureship. Madison, WI, US.
1999. Safety Monitoring and Science in Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1999. Treatment Comparisons Based on Two-Dimensional Safety and Efficacy Alternatives in Oncology Trials. Invited. University of Waterloo. Waterloo, CA.
1998. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Toxicity in Phase I/II Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1998. Practical Guidelines for Dose-Finding with the Continual Reassessment Method in Phase I Clinical Trials. Invited. H. Lee Moffitt Cancer Center. Tampa, FL, US.
1998. Practical Guidelines for Dose-Finding with the Continual Reassessment Method in Phase I Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1998. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. Department of Biostatistics, Memorial Sloan Kettering. New York, NY, US.
1997. Extensions and Applications of a Bayesian Strategy for Monitoring Multiple Outcomes in Clinical Trials. Invited. University of Southampton. Southampton, GB.
1997. New Graphical Methods for Evaluating and Improving Goodness-of-Fit in Survival Analysis With the Cox Model. Conference. MD Anderson Cancer Center. Houston, TX, US.
1997. Variable Selection in Regression Via Repeated Data Splitting. Conference. 29th Symposium on the Interface Between Computing Science and Statistics. Houston, TX, US.
1997. Visiting Lecturer, Medical and Pharmaceutical Statistics Research Unit. Visiting. University of Reading. Reading, GB.
1996. Estimating Genomic Category Probabilities from FISH Counts with Misclassification. Conference. Rice University. Houston, TX, US.
1996. Bayesian Design and Monitoring Strategies for Single-Arm Clinical Trials. Invited. University of Uppsala. Uppsala, SE.
1996. Statistical Design of Phase II and Phase III Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1996. A New Statistical Strategy for Monitoring Multiple Adverse and Efficacy Outcomes in Phase I/II Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1996. A Strategy for Monitoring Multiple Outcomes in Developmental Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1996. Statistical Designs for Phase II and Phase III Cancer Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1995. Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes. Conference. Houston Area Chapter, American Statistical Association. Houston, TX, US.
1995. Statistical Designs for Phase II and Phase III Cancer Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1995. Balancing on Prognostic Factors in Randomized Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1995. Statistical Data Analysis: Fitting Equations to Data. Conference. MD Anderson Cancer Center. Houston, TX, US.
1995. A Semiparametric Gamma-Poisson Regression Model for Repeated Interval Counts with Covariates. Invited. University of Waterloo. Waterloo, CA.
1995. Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes. Conference. Rice University. Houston, TX, US.
1995. A Strategy for Selecting Treatments for Phase II Study: The Phase I 1/2 Design. Conference. MD Anderson Cancer Center. Houston, TX, US.
1994. Analysis of Prognostic Factors. Conference. MD Anderson Cancer Center. Houston, TX, US.
1994. Phase II Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1994. Statistical Designs for Continuous Monitoring of Single-Arm Clinical Trials with Multiple Outcomes. Conference. MD Anderson Cancer Center. Houston, TX, US.
1994. Bayesian Sequential Monitoring Designs For Single-Arm Clinical Trials with Multiple Outcomes. Conference. Society for Clinical Trials. Houston, TX, US.
1994. A Statistical Design for the CD34 Allogeneic Bone Marrow Transplant Trial: Application of the Thall-Simon-Estey Monitoring Strategy. Conference. MD Anderson Cancer Center. Houston, TX, US.
1994. A Quantitative Method for Evaluating Quality of Life in Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1994. Prevalence of a Transient Condition: A Quantitative Method for Evaluating Quality of Life in Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1993. Practical Bayesian Stopping Rules for Clinical Oncologist. Invited. Institut Gustave-Roussy. Paris, FR.
1993. Practical Bayesian Stopping Rules for Clinical Oncologists. Invited. Institut Curie. Paris, FR.
1993. Practical Bayesian Stopping Rules for Clinical Oncologists. Conference. MD Anderson Cancer Center. Houston, TX, US.
1993. New Designs for Clinical Trials With Multiple Endpoints. Conference. MD Anderson Cancer Center. Houston, TX, US.
1993. Q-Twist: A Quality-of-Life Oriented Statistic for Cancer Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1993. Results of Accelerated Radiotherapy with Carboplatin in Glioblastomas. Conference. MD Anderson Cancer Center. Houston, TX, US.
1993. Design of Phase II Bone Marrow Transplant Studies. Conference. MD Anderson Cancer Center. Houston, TX, US.
1993. Bayesian Death in the Clinic. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. A Bayesian Design for a Phase IIB Study of Transretinoic Acid + Idarubicin in APL Patients. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. Phase II Trials With Continuous Monitoring: a Bayesian Design. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. Statistical Designs for Phase II Clinical Trials. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. Regression: Fitting Equations to Data. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. Confidence Intervals and Multiple Testing. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. The Mythology of P-values: Hypothesis Testing in the Clinic. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. The Mythology of P-values: Hypothesis Testing in the Clinic. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. Your Friend, the Sample Statistic. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. How to Survive Statistics. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. Basic Concepts in Statistics. Conference. MD Anderson Cancer Center. Houston, TX, US.
1992. A Bayesian Strategy for Screening Cancer Treatments Prior to Phase II Evaluation. Conference. MD Anderson Cancer Center. Houston, TX, US.
1991. A Bayesian Treatment Selection Design for Evaluating New Therapies in Leukemia. Conference. MD Anderson Cancer Center. Houston, TX, US.
1991. A Comparative Analysis of Complete Remission and Survival in AML Patients Treated with High Dose ARA-C Alone or +GM-CSF. Conference. MD Anderson Cancer Center. Houston, TX, US.
1991. Some Covariance Models for Longitudinal Count Data with Overdispersion. Conference. Rice University. Houston, TX, US.
1988. Optimal Two-Stage Designs for Clinical Trials with Binary Response. Invited. Washington Statistical Society. Washington, DC, US.
1983. Assessment of Stratum-Covariate Interactions in Cox's Proportional Hazards Regression Model. Invited. Society for Clinical Trials Meeting. St. Louis, MO, US.
1983. Gambling and Games of Chance. Invited. Washington Statistical Society. Washington, DC, US.
1979. Cluster Shock Models. Invited. American Statistical Association Meeting. Washington, DC, US.

Regional Presentations

2025. Bayesian Precision Treatment Screening and Selection Using Utilities of Response and Toxicity. Invited. Biostatistics and Bioinformatics Seminar, Division of Epidemiology and Biostatistics, University of Illinois at Chicago Cancer Center, October 14, 2025. Illinois, Chicago, US.
2024. Generalized Phase 1-2 Designs to Maximize Long Term Therapeutic Success Rate. Invited. Biostatistics and Bioinformatics Seminar, Division of Epidemiology and Biostatistics, University of Illinois at Chicago Cancer Center, December 10, 2024. Illinois, Chicago, US.
2021. Bayesian Precision Medicine Designs for Cancer Clinical Trials. Department of Biostatistics and Bioinformatics. Invited, US.
2021. Fatal Statistical Practices in Medical Research. Conference. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center, US.
2020. A New Hybrid Phase I-II-III Clinical Trial Paradigm. Invited, US.
2020. How to Avoid Crippling Potential New Cancer Treatments. Conference. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center, US.
2019. Bayesian Nonparametric Survival Regression for Optimizing Precision Dosing of Intravenous Busulfan in Allogeneic Stem Cell Transplantation. Invited. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center. Houston, TX, US.
2016. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Early Phase Biometrics. Invited. Boston, MA, US.
2014. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. Paris, FR.
2013. Bayesian Sequentially Adaptive Clinical Trial Design: General Concepts and Applications. Invited. Houston, TX, US.
2013. Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy. Invited. Montreal, CA.
2012. Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy. Invited. Madison, WI, US.
2012. Innovative Bayesian Methods for Early Phase Clinical Trials. Conference. Graduate School of Biomedical Sciences. Houston, TX, US.
2010. Innovative Bayesian Methods for Early Phase Clinical Trials. Conference. MD Anderson Cancer Center, US.
2010. Bayesian Adaptive Dose Finding Designs for Early Phase Clinical Trials. Invited. Houston, TX, US.
2010. Select-and-Test Designs for Phase II-III Clinical Trials. Invited. Clinical Trial Design and Biostatistics Workshop. Kyoto, JP.
2009. Optimizing a Two Agent Combination Based On Utilities of Ordinal Toxicity and Efficacy Outcomes. A One-Day Symposium to Honor Ed Gehan. Invited. Washington, DC, US.
2008. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times. Invited. Charleston, SC, US.
2008. Patient-Specific Dose-Finding Based on Bivariate Outcomes and Covariates. Invited. Pittsburgh, PA, US.
2007. A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases. Invited. Washington, DC, US.
2007. Improving the Reliability and Precision of Phase 2 Clinical Trials. Invited. Cancer Therapy Evaluation Program. Rockville, MD, US.
2006. Two New Bayesian Designs for Dose-Finding Trials. Invited. Solid Tumor Oncology and Hematologic Oncology Grand Rounds. New York, NY, US.
2005. Recent Advances in Bayesian Adaptive Dose-Finding. Invited. Emeryville, CA, US.
2003. Adaptive Bayesian Designs for Clinical Trials. Invited. Rockville, MD, US.
2003. Covariate-Adjusted Adaptive Randomization in a Sarcoma Trial with Multi-Stage Treatments. Invited. Philadelphia, PA, US.
2002. Bayesian Methods in Clinical Trials: Recent Practical Innovations in Phase I and II Studies. Invited. Grand Rounds. Washington, DC, US.
2002. Treatment Comparisons Based on Two-Dimensional Safety and Efficacy Alternatives in Oncology Trials. Invited. Richmond, VA, US.
2001. Multi-course Treatment Strategies for Clinical Trials of Rapidly Fatal Diseases. Conference. Texas A & M University. College Station, TX, US.
2000. Evaluating Multiple Treatment Courses in Clinical Trials. Invited. Columbia, MO, US.
1999. Science and Safety Monitoring in Clinical Trials. Invited. Geneva, CH.
1999. New Dose-Finding Methods for Early Phase Clinical Trials. Invited. Chicago, IL, US.
1998. Decision-Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes. Conference. Texas A & M University. College Station, TX, US.
1998. Approximate Bayesian Evaluation of Multiple Treatment Effects, Medical and Pharmaceutical Statistics Research Unit. Invited. Reading, GB.
1997. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. Minneapolis, MN, US.
1996. Variable Selection in Regression Via Repeated Data Splitting. Conference. University of Texas. Dallas, TX, US.
1996. Randomized Selection and Testing Designs for Phase II/III Clinical Trials. Invited. Bern, CH.
1995. Statistical Methods for Design and Conduct of Clinical Trials. Conference. University of Texas Southwestern Medical Center. Dallas, TX, US.
1994. Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes. Conference. Programs in Mathematical Sciences, University of Texas. Dallas, TX, US.
1994. Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes. Invited. Freiburg, DE.
1992. Test-Based Variable Selection via Cross-Validation. Invited. Rockville, MD, US.
1987. Two-Stage Designs. Cancer Therapy Evaluation Program. Invited. Bethesda, MD, US.

National Presentations

2023. New paradigms for dose finding: A response to FDA Project Optimus. Conference. Biostatistics Lunch Discussion Series, Dept of Biostatistics, MD Anderson Cancer Center, US.
2023. Discussant for the talk “Flexible modeling of adaptive treatment strategies for censored outcomes”. Invited. E. Moodie, US.
2023. A robust Bayesian phase II design for monitoring a time-to-event endpoint. Invited. Pharmaceutical Statistics Journal Club Webinar, US.
2023. Bayesian precision treatment screening and selection using elicited utilities of response and toxicity. Invited. In the session “New Methods for Improved Decision-Making in Precision Medicine”, Joint Statistical Meetings, Toronto, Ontario, CA.
2022. Bayesian Personalized Treatment Selection for Advanced Breast Cancer. Invited. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center. Houston, TX, US.
2022. A Bayesian group sequential enrichment design with adaptive regression of response and survival time on baseline biomarkers. Invited. In the session “Adaptive Enrichment Designs in Clinical Trials”, Joint Statistical Meetings. Washington, DC, US.
2022. Evolution of Bayesian Clinical Trial Methodologies: Cooking Up Designs for 30 Years. Invited. In the session, “Three Decades of Bayesian Clinical Trial Designs: From Stopping Rules to Hierarchical Models for Precision Medicine”. Organizer: Ruitao Lin, ENAR Annual Meeting, US.
2022. Discussant for the session “Trailblazing SMART Design and Statistical Learning for Precision Health”. Invited. Organizer: Kelley Kidwell, ENAR Annual Meeting, US.
2022. A Randomized Multicenter Pilot Study of T-Cell Therapy for Acute Respiratory Distress Syndrome in COVID-19 ICU Patients. Invited. Informal Biostatistics Lunch Discussion Series, Department of Biostatistics, MD Anderson Cancer Center. Houston, TX, US.
2021. A Basket Trial Design to Optimize Dose and Schedule Based on Delayed Response and Toxicity. Invited. In the session “Statistical Considerations for Master Protocols in I-O and Cell Therapy.” International Chinese Statistical Association meeting, US.
2021. A New Hybrid Phase I-II-III Clinical Trial Paradigm. Invited. Stat4Onc Annual Conference, US.
2021. A New Hybrid Phase I-II-III Clinical Trial Paradigm. Invited. Cytel Webinar on Bayesian Methods, US.
2021. Bayesian Clinical Trial Design and Data Analysis in Oncology. Invited. Radiation Oncology Education Collaborative Study Group Spring Symposium, US.
2020. Bayesian nonparametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. Invited. International Chinese Statistical Association, Applied Statistics Symposium, US.
2020. Bayesian nonparametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. Invited. Presented virtually in the session “Recent Developments in Statistical Methods for Precision Medicine.” Joint Statistical Meetings, US.
2020. A New Hybrid Phase I-II-III Clinical Trial Paradigm. Awarded Best Paper Published in Biometrics in 2019. Invited. in the Showcase Session, International Biometric Society Annual Meeting, held virtually due to COVID-19 pandemic. Co-presented with Andrew Chapple, US.
2020. A New Hybrid Phase I-II-III Clinical Trial Paradigm. OncoStat Conference, Stanford University, Palo Alto, Conference canceled due to COVID-19 pandemic. Invited. A New Hybrid Phase I-II-III Clinical Trial Paradigm. OncoStat Conference, Stanford University, Palo Alto, Conference canceled due to COVID-19 pandemic.
2020. Statistical Remedies for Flawed Conventions in Medical Research. Invited. Tucson, AZ, US.
2019. Two Bayesian Clinical Trial Design for Precision Medicine in Oncology. Invited. In the session 'The Importance of Clinical Trial Design: Registry Trials, Novel Designs and Common Mistakes To Avoid', Cord Blood Connect Annual Meeting, US.
2019. Bayesian Clinical Trial Designs to Evaluate Subgroup-Specific Treatment Effects. Invited. In the session 'Recent Developments in Novel Clinical Trial Design and Analysis for Precision Medicine' Invited ENAR, Biometrics Section, Biopharmaceutical Section. Joint Statistical Meetings, US.
2019. Subgroup-Specific Dose Finding in Phase I Clinical Trials Based on Time to Toxicity Allowing Adaptive Subgroup Combination. Invited. In the session 'Using adaptive treatment strategies to give the right patient the right dose at the right time' ICSA Applied Statistics Symposium. Raleigh, NC, US.
2019. Bayesian Oncology Clinical Trial Designs with Subgroup-Specific Decisions. Invited. Stat4Onc Annual Meeting. Hartford, CT, US.
2019. Roundtable discussion leader, 'Practical Issues in Clinical Trial Design and Analysis for Precision Medicine'. Invited. ENAR Meeting of the International Biometric Society. Philadelphia, PA, US.
2019. Two-Bayesian Clinical Trial Designs for Precision Medicine in Oncology. Invited. 2019 TCT Meetings of the ASBMT and CIBMTR. Houston, TX, US.
2018. Bayesian Clinical Trial Designs to Evaluate Precision Medicine in Oncology. Invited. 4th International Conference on Big Data and Information Analytics. Houston, TX, US.
2018. Bayesian Clinical Trial Designs to Evaluate Precision Medicine in Oncology. Invited. The Statistics and Applied Mathematics Institute Workshop on Precision Medicine. Raleigh, NC, US.
2018. Discussant, Drug Information Association. Invited. "Novel Designs in Dose Finding", US.
2018. Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer. Invited. In the Session "Recent Advances in Practical Clinical Trial Design". Atlanta, GA, US.
2018. Roundtable discussion leader. Invited. "Practical Issues in Clinical Trial Design and Analysis". Atlanta, FL, US.
2017. Some Caveats for Outcome Adaptive Randomization in Two Arm Clinical Trials. Invited. In the session "Adaptive randomization: a balance between innovation, bias reduction, regulatory and ethical considerations". Washington, DC, US.
2017. Parametric Dose Standardization for Two-Agent Phase I-II Trials with Ordinal Efficacy and Toxicity. Invited. In the session, "Recent Developments in Early Phase Dose-Finding". Chicago, IL, US.
2017. Parametric Dose Standardization for Two-Agent Phase I-II Trials with Ordinal Efficacy and Toxicity. Invited. Bringing Adaptive Trials into the Real World. Washington, DC, US.
2016. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times. Invited. JASA Applications and Case Studies. Chicago, IL, US.
2016. Discussant, Showcase of the Power of Statistics on Evaluating Dynamic Treatment Regimes Leading Toward Personalized Health Care, Invited Paper Session. Invited. Co-Sponsors, Eastern North American Region and International Chinese Association. Chicago, IL, US.
2016. Caveats for Outcome Adaptive Randomization in Comparative Clinical Trials. Invited. 9th Annual Conference on Statistical Issues in Clinical Trials. Philadelphia, PA, US.
2016. Adaptive Treatment Assignment: Getting Personal in Oncology. Invited. Eastern North American Region of the International Biometric Society. Austin, TX, US.
2016. Visiting Research Scientist, INSERM Unit 1138, Data Science and Personalized Medicine. Visiting. Paris, FR.
2015. Bayesian Designs for Early Phase Clinical Trials. Invited. Kidney Cancer Association Annual Meeting. Miami, FL, US.
2015. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. 2015 ASA Biopharmaceutical Section. Washington, DC, US.
2015. Bayesian Adaptive Optimization of Sedative Dose in Preterm Being Treated for Respiratory Distress Syndrome. Invited paper session, Bayesian Adaptive Designs for Better Clinical Decision Making. Invited. WNAR. Seattle, WA, US.
2015. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. Greehey Children's Cancer Research Instititute. San Antonio, TX, US.
2014. Utility-Based Optimization of Schedule-Dose Regimes based on the Times to Response and Toxicity. In the session Designs and Analyses of Studies with Small Sample Sizes. Invited. Joint Statistical Meetings. Boston, MA, US.
2014. Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. Presented jointly with Yanxun Xu, AML Hackathon, DREAM 9. Invited. Houston, TX, US.
2014. Adaptively Optimizing Schedule-Dose Regimes based on Utilities of Competing Event Times. In the session Design of Clinical Trials. Invited. International Indian Statistical Association Conference. Riverside, CA, US.
2014. Utility-Based Optimization of Schedule-Dose Regimes based on the Times to Response and Toxicity. Invited. International Chinese Statistical Association and Korean International Statistical Society Joint Applied Statistics Symposium. Portland, OR, US.
2014. Discussant, Clinical Trials for Adaptive Intervention Designs: Design and Conduct of Sequential Multiple Assignment Randomized Trials, Half-day workshop. Invited. Society for Clinical Trials, Annual Meeting. Philadelphia, PA, US.
2014. Optimizing Schedule-Dose Regimes in Early Phase Clinical Trials. Invited. New York, NY, US.
2014. Utility-Based Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. Ann Arbor, MI, US.
2014. Bayesian Dose-Finding in Two Treatment Cycles Using Joint Efficacy-Toxicity Utilities. Invited. Ann Arbor, MI, US.
2014. Bayesian Clinical Trial Design: 23 Years of Theory and Practice. Invited. Council of Texas Statisticians Annual Meeting. Dallas, TX, US.
2014. Bayesian Dose-finding Methods for Targeted Agents in Early Phase Clinical Trials. In the session Recent Developments in Personalized Medicine. Invited. ENAR Meeting of the International Biometric Society. Baltimore, MD, US.
2013. Bayesian Dose-Finding in Two Treatment Cycles based on the Joint Utility of Efficacy and Toxicity in the session "Personalized Medicine and Dynamic Treatment Regimes". Invited. 10th International Conference on Health Policy Statistics (ICHPS). Chicago, IL, US.
2013. Dose-Finding Based on Elicited Joint Utilities of Ordinal Toxicity and Efficacy. Invited. University of Michigan School of Public Health. Ann Arbor, MI, US.
2013. Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes. Invited. Pre-ASCO Workshop on Novel Designs for Early Phase Studies. Chicago, IL, US.
2013. Bayesian Dose Finding in Two Treatment Cycles based on the Joint Utility of Efficacy and Toxicity. Invited. 33rd Society for Clinical Trials. Boston, MA, US.
2013. Bayesian Dose-Finding in Two Treatment Cycles based on the Joint Utility of Efficacy and Toxicity, In the session, Multi-State Randomized Clinical Trials for the Development of Dynamic Treatment Regimes. Invited. 2013 Annual Meeting. Boston, MA, US.
2013. Practical Adaptive Bayesian Methods for Early Phase Clinical Trials, In the workshop, Designs for Contemporary Early-Phase Clinical Trials, In the pre-ASCO workshop. Invited. American Society for Clinical Trials. Chicago, IL, US.
2012. Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. Invited. UAI Workshop on Causal Structure Learning. Catalina Island, CA, US.
2012. Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy. In the session, Dose Selection in Clinical Trials. Invited. Joint Statistical Meeting. San Diego, CA, US.
2012. Practical Challenges in the Design, Conduct, and Analysis of Randomized Trials of Dynamic Treatment Regimes in Oncology. Invited. 21st Annual Applied Statistics Symposium. Boston, MA, US.
2012. Webinar, "Dysfunctional Paradigms in Clinical Trials: Some Bayesian Alternatives". Conference. Section on Bayesian Statistical Science, US.
2012. Dysfunctional Paradigms in Clinical Trials: Our Conventions Are Killing Us. In the session “Decision Making in the Process of Drug Development. Invited. Midwest Biopharmaceutical Statistics Workshop. Muncie, IN, US.
2012. Practical Issues in the Design, Conduct, and Analysis of Randomized Oncology Trials Comparing Dynamic Treatment Regimes. In the session, Recent Advances in Dynamic Treatment Regimes Research. Invited. ENAR Meeting of the International Biometric Society. Washington, DC, US.
2011. Patient-Specific Dose-Finding Based on Bivariate Efficacy-Toxicity Outcomes and Prognostic Covariates. Invited. Nashville, TN, US.
2011. Practical Issues in Bayesian Adaptive Designs for Early Phase Clinical Trials. Leader, Roundtable discussion, sponsored by the Section on Bayesian Statistical Science. Invited. Joint Statistical Meetings. Miami, FL, US.
2011. Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion. In the session Phase I/II clinical studies: safety versus efficacy. Invited. 20th Annual Applied Statistics Symposium. New York, NY, US.
2011. Establishing Priors for Bayesian Clinical Trials. Department of Biostatistics. Invited. New York, NY, US.
2011. Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion. In the session "Adaptive Designs for Clinical Trials". Invited. International Conference on Design of Experiments. Memphis, TN, US.
2011. Optimizing the Bolus and Concentration of a Drug Administered by Continuous Infusion. In the session “Innovative Adaptive Designs in Early-Phase Oncology Clinical Trials. Invited. ENAR Meeting of the International Biometric Society. Miami, FL, US.
2010. Bayesian Designs for Prostate Cancer Trials Involving Androgen Receptor Signaling. Androgen Receptor Signaling in Prostate Cancer: Translating Biology into Clinical Practice. Invited. NCI. Unknown, US.
2010. A Phase II-III Select-and-Test Design Based on Treatment Failure Time and Toxicity: Evaluating Chemotherapies for Choroid Plexus Carcinomas in Children. Invited. Society of Pediatric Oncology. Boston, MA, US.
2010. Prior Elicitation in Bayesian Clinical Trial Design. Invited. Intensive Summer Research Program on Semiparametric Bayesian Inference: Applications in Pharmacokinetics and Pharmacodynamics. Triangle Park, NC, US.
2010. A Bayesian Geometric Phase II-III Select-and-Test Design Based On Treatment Failure Time and Toxicity. Invited. 19th Annual Applied Statistics Symposium. Indianapolis, IN, US.
2010. Select-and-Test Designs for Phase II-III Clinical Trials. Invited. Yokohama, JP.
2010. Application of a Bayesian Doubly Optimal Group Sequential Design for Clinical Trials: Localized Surgery versus Chemotherapy for Non-Small-Cell Lung Cancer. Invited. Frontiers of Statistical Decision Making and Bayesian Analysis: A Conference in Honor of James O. Berger. San Antonio, TX, US.
2010. Using Prior Information and Elicited Utilities for Adaptive Decision Making in Phase I/II Trials. Invited. In the session “Recent Developments of Bayesian Methods for Combining Data from Multiple Sources.”. New Orleans, LA, US.
2010. Patient-Specific Dose-Finding Based On Bivariate Efficacy-Toxicity Outcomes and Prognostic Covariates. Invited, NC, US.
2009. Navigating the Rocky Shoals of Adaptive Trial Design and Execution. Invited. Scientific Advances in Adaptive Clinical Trial Designs Workshop. Bethesda, MD, US.
2009. Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Clinical Trials. Invited. Workshop in Phase I Designs with a Focus on the Continual Reassessment Method, US.
2009. Bayesian Designs for Clinical Trials with Dynamic Re-Randomization. Invited. Biostatistics Workshop in Cancer Research. Toronto, US.
2009. Optimizing a Two Agent Combination Based On Utilities of Ordinal Toxicity and Efficacy Outcomes. Invited. A One-Day Symposium to Honor Ed Gehan. Department of Biostatistics, Bioinformatics and Biomathematics. Washington, DC, US.
2009. A Prostate Cancer Trial with Re-Randomization: How we spent a decade studying twelve dynamic treatment regimes. Invited. ENAR Meeting of the International Biometric Society. San Antonio, TX, US.
2009. A Geometric Phase II-III Select-and-Test Design Based on Treatment Failure Time and Toxicity. Innovation in Choroid Plexus Tumor Research. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. A Geometric Phase II-III Select-and-Test Design Based on Treatment Failure Time and Toxicity. Invited. Innovation in Choroid Plexus Tumor Research. Houston, TX, US.
2009. Patient-Specific Dose-Finding Based On Bivariate Outcomes and Covariates. Invited. Baltimore, MD, US.
2009. Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials. Invited. Bayesian Biostatistics Conference. Houston, TX, US.
2009. Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials. Invited. Bayesian Biostatistics Conference. Houston, TX, US.
2008. Patient-Specific Dose-Finding Based on Bivariate Outcomes and Covariates. Invited. FDA/Industry Workshop, "Special Topics in Oncology Drug Development". Arlington, VA, US.
2008. Bayesian Methods for Multidimensional Treatment Effects. Invited. Annual Conference on Statistical Issues in Clinical Trials: From Bench to Bedside to Community. Philadelphia, PA, US.
2008. Select-and-Test Designs for Phase II-III Clinical Trials, Forum on "Decisions at the Phase II / Phase III Interface". Invited. American Association for Cancer Research Annual Meeting. San Diego, CA, US.
2008. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times. In the session "Dynamic Treatment Regimes: Practice and Theory". Invited. ENAR Annual Meeting of the International Biometric Society. Arlington, VA, US.
2007. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times. Invited. Palo Alto, CA, US.
2007. Assessing Two-Stage Treatment Strategies for Metastatic Renal Cell Cancer. Invited. Sixth Annual Kidney Cancer Symposium. Chicago, IL, US.
2007. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times Subject to Interval Censoring. Invited. Joint Statistical Meetings. Salt Lake City, UT, US.
2007. Designing Clinical Trials to Evaluate Dynamic Treatment Regimes, Introductory Overview Lecture: Adaptive Designs and Other Emerging Issues in Clinical Trials. Invited. Joint Statistical Meetings. Salt Lake City, UT, US.
2007. Practical Bayesian Adaptive Randomization in Clinical Trials, "Alternatives to Phase III Trial Design" Education Session. Invited. American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
2007. Accounting for Heterogeneity in Phase II Clinical Trials Using Bayesian Methods, in the session, Clinical Trials, Part I: Recent Innovations in Oncology Clinical Trials. Invited. American Association for Cancer Research Annual Meeting. Los Angeles, CA, US.
2007. Patient-Specific Dose-Finding Based On Bivariate Outcomes With Covariates. Invited. ENAR Meeting of the International Biometric Society. Atlanta, GA, US.
2006. A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases. Invited. Joint Statistical Meetings. Seattle, WA, US.
2006. Adaptive Randomization in Sarcoma Trials: Past and Future. Invited. Sarcoma Alliance for Research through Collaboration (SARC) Biannual Meeting. Atlanta, GA, US.
2005. Patient-Specific Dose-Finding: A New Method Based on Efficacy, Toxicity and Prognostic Covariates. Invited. Neurology Grand Rounds. Bethesda, MD, US.
2005. Some Bayesian Methods for Clinical Trial Design and Analysis. Invited. 12th Annual Biopharmaceutical Applied Sciences Symposium. Savannah, GA, US.
2005. Multi-State Treatment Trials in Oncology. Invited. Dynamic Treatment Regimes Network Meeting. Ann Arbor, MI, US.
2005. Adaptive Multi-Course Treatment Strategies in Two Oncology Trials. Invited. Joint Statistical Meetings, Session on "Dynamic Treatment Regimes". Minneapolis, MN, US.
2005. On the Hazards of Survival Time Comparisons in the Presence of Recurrent Disease. Invited. Sarcoma Alliance for Research through Collaboration (SARC) Biannual Meeting. Orlando, FL, US.
2005. Dose-Finding Based On Efficacy and Toxicity in Phase I/II Clinical Trials. In the session, Recent Developments in Sequential Clinical Trials Methodology. Invited. ENAR 2005 Meeting of the International Biometric Society. Austin, TX, US.
2005. Some Phase 23 Clinical Trial Designs. Biostatistical Issues and the Design of Type 1 Diabetes TrialNet Protocols. Invited. NIDDK Meeting. Bethesda, MD, US.
2004. Bayesian Adaptive Methods for Clinical Trial Design and Conduct. Future Clinical Trials Issues in Multiple Sclerosis. Invited. Annual Meeting of the Multiple Sclerosis Society. Washington, DC, US.
2004. Dose-Finding Based On Efficacy-Toxicity Trade-Offs. Invited. Bethesda, MD, US.
2004. Bayesian Sensitivity Analyses of Confounded Treatment Effects in Survival Analysis. Invited. 25th Spring Symposium, Advances in Survival Analysis Methods for Clinical Trials. Piscataway, NJ, US.
2004. A Donor Lymphocyte Infusion Trial: Adaptively Optimizing Infusion Times. In the Jiann-Ping Hsu Session on Pharmaceutical/Regulatory Sciences session. Invited. Adaptive Designs for Clinical Trial, 2004 Applied Statistics Symposium. San Diego, CA, US.
2004. Dose-Finding Based On Efficacy-Toxicity Trade-Offs. Invited. Design and Analysis of Phase II Clinical Trials, 25th Annual Meeting. New Orleans, LA, US.
2004. Dose-Finding With Two Agents in Phase I Oncology Trials. Invited. Recent Developments in Phase I Trials Design, ENAR 2004 Meeting of the International Biometric Society. Pittsburgh, PA, US.
2003. (i) Covariate-Adjusted Adaptive Randomization in a Sarcoma Trial with Multi-Stage Treatments and (ii) Practical Adaptive Decision-Making in Oncology Clinical Trials. Invited. Memphis, TN, US.
2003. Biostatistical Consulting: The Doctor-Statistician relationship. Roundtable Luncheon, Section on Bayesian Statistical Sciences. Invited. American Statistical Association Joint Meetings. San Francisco, CA, US.
2003. Covariate-Adjusted Adaptive Randomization in a Multi-Stage Sarcoma Trial. Invited. Harvard Schering-Plough Workshop on Development and Approval of Oncology Drug Products: Impact of Statistics. Boston, MA, US.
2003. Adaptive Decision-Making in a Lymphocyte Infusion Trial. Invited. Conference on New Directions in Experimental Design. Chicago, IL, US.
2003. Adaptive Decision-Making in a Lymphocyte Infusion Trial. Invited. Chicago, IL, US.
2003. Evaluating Therapeutic Strategies in Multi-Course Clinical Trials. Invited. ENAR 2003 Spring Meeting of the International Biometric Society. Tampa, FL, US.
2002. Some Bayesian Approaches to Sarcoma Trials. Invited. Connective Tissue Oncology Society Annual Meeting. San Francisco, CA, US.
2002. Dose-Finding with Two Agents in Phase I Oncology Trials. Invited. New Statistical Methods for Dose-Finding, Henry Stewart Conferences. Washington, CT, US.
2002. Seamlessly Expanding a Randomized Phase II Trial to a Phase III Trial, Session on Recent Advances in Clinical Trial Design. Invited. WNAR Meeting of the International Biometric Society. Los Angeles, CA, US.
2002. Adaptive Design Strategies for Gene Therapy Trials. Workshop Cancer-How to Design Cancer Gene Therapy Clinical Trials. Invited. American Society of Gene Therapy 5th Annual Meeting. Boston, MA, US.
2002. Adaptive Decision Making in a Lymphoctye Infusion Trial. Invited. ENAR Meeting of the International Biometric Society, Session on "Outcome Adaptive Methods in Early Phase Clinical Trials". Alexandria, VA, US.
2002. Seamlessly Expanding a Randomized Phase II Trial to a Phase III Trial. Invited. Statistics of Multi-Center Trials, Henry Stewart Conferences. Washington, DC, US.
2001. A Hierarchical Bayesian Model for an Activity Trial of Gleevec in Sarcoma: Borrowing Strength Across Disease Subtypes. Invited. Connective Tissue Oncology Society Consortium Meeting. West Palm Beach, FL, US.
2001. Multi-course Treatment Strategies for Clinical Trials of Rapidly Fatal Diseases. Invited. Carnegie Mellon University Bayesian Workshop VI. Pittsburgh, PA, US.
2001. Seamlessly Expanding a Randomized Phase II Trial to Phase III. Invited. Joint Statistical Meetings, Section on Bayesian Statistics. Atlanta, GA, US.
2000. Bayesian Methods in Early Phase Clinical Trial Design. Invited. Joint Statistical Meetings, Section on Bayesian Statistics. Indianapolis, IN, US.
2000. Treatment Comparisons Based on Two-Dimensional Safety and Efficacy Alternative in Clinical Trials. Invited. Applied Statistics Symposium. Piscataway, NJ, US.
2000. Approximate Bayesian Evaluation of Multiple Treatment Effects: An Alternative to Hypothesis Testing. Invited. Cambridge, MA, US.
2000. Evaluating Multiple Treatment Courses in Clinical Trials. Invited. ENAR Meeting of the International Biometric Society, Session on Design and Analysis of Clinical trials With Multiple Endpoints. Chicago, IL, US.
1999. Approximate Bayesian Evaluation of Multiple Treatment Effects: An Alternative to Hypothesis Testing. Invited. Basel, CH.
1999. Treatment Comparisons based on Two-Dimensional Safety and Efficacy Alternatives in Oncology Trials. Invited. ENAR Spring Meeting. Atlanta, GA, US.
1998. A Strategy for Dose-Finding and Safety Monitoring Based on Safety and Efficacy Outcomes in Phase I/II Clinical Trials. Invited. 1998 WNAR Annual Meeting, IMS Western Regional Meeting. San Diego, CA, US.
1998. Some Experiences Applying the Continual Reassessment Method at M.D. Anderson Cancer Center. Invited. Drug Information Association's 34th Annual Meeting. Boston, MA, US.
1998. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. ENAR Annual Meeting. Pittsburgh, PA, US.
1998. Parametric Likelihoods for Multiple Non-Fatal Competing Risks and Death. Invited. New York, NY, US.
1998. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. Drug Information Association's Annual Symposium, Global Challenges and Strategies in the Pharmaceutical Industry, Recent Developments in Design and Analysis of Oncology Trials. Hilton Head, SC, US.
1997. Parametric Likelihoods for Multiple Nonfatal Competing Risks and Death. Presented in the session Topics in Lifetime Data Analysis in Medical Research. Invited. Silver Jubilee Annual Meeting of the Statistical Society of Canada. Fredericton, CA.
1997. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. Pittsburgh, PA, US.
1997. Variable Selection in Regression Via Repeated Data Splitting. Invited. ENAR Spring Meeting. Memphis, TN, US.
1996. A Strategy for Monitoring Multiple Outcomes in Early Phase Trials, or How to Conduct Single-Arm Trials if You Must. Invited. Symposium on Bayesian Approaches to Clinical Trials. Brookline, MA, US.
1996. Estimating Genomic Category Probabilities from Fluorescent in situ Hybridization Counts with Misclassification. Invited. 1996 Eastern North American Region of the International Biometric Society Meeting, Basic Science Session. Richmond, VA, US.
1996. Semiparametric Regression Analysis for Recurrent Event Interval Counts. Invited. 1996 ENAR Spring Meeting. Richmond, VA, US.
1995. Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes. Invited. Rochester, MN, US.
1994. Bayesian Sequential Monitoring Designs For Single-Arm Clinical Trials with Multiple Outcomes. Invited. International Biometric Society. Cleveland, OH, US.
1993. Sample Size and Monitoring Criteria for Bayesian Phase II Clinical Trials. Invited. 14th Annual Meeting. Orlando, FL, US.
1992. Practical Bayesian Guidelines for Phase IIB Clinical Trials. Invited. 1992 Annual Meeting. Philadelphia, PA, US.
1991. Some Covariance Models for Longitudinal Count Data with Overdispersion. Invited. Biometric Society WNAR Meeting. Santa Barbara, CA, US.
1990. Some Covariance Models for Longitudinal Count Data with Overdispersion. Invited. International Biometric Society ENAR Meeting. Baltimore, MD, US.
1988. Mixed Poisson Likelihood Regression Models for Longitudinal Interval Count Data. Invited. Richmond, VA, US.
1988. Optimal Two-Stage Designs for Clinical Trials with Binary Response. Invited. Society for Clinical Trials Meeting. San Diego, CA, US.
1987. A Two-stage Design for Choosing Among Several Experimental Treatments and a Control in Phase III Clinical Trials. Invited. Society for Clinical Trials Meeting. Atlanta, GA, US.
1986. Mixed Poisson Likelihood Regression Models for Longitudinal Interval Count Data. Invited. American Statistical Association Meetings. Chicago, IL, US.
1983. Assessment of Stratum-Covariate Interactions in Cox's Proportional Hazards Regression Model. Invited. Rockville, MD, US.

International Presentations

2024. Landscape Seminar,. Invited. Department of Mathematical Sciences, Bath University, United Kingdom, May 3, 2024. United Kingdom, GB.
2022. Bayesian Personalized Treatment Selection for Advanced Breast Cancer. Invited. Cancer Biostatistics Seminar, Department of Biostatistics, University of Michigan, US.
2019. Applications of Bayesian Precision Medicine. Invited. Keynote Address, International Society for Clinical Biostatistics, Annual Meeting. Leuven, BE.
2015. Bayesian Utility-Based Sequentially Adaptive Designs for Early Phase Clinical Trials Symposium Early Phase Dose Finding Methodology. Invited. Pierre and Marie Curie University. Paris, FR.
2013. Bayesian Designs for Early Phase Clinical Trials in the session "Shared Challenges of Small Group Trials". Invited. 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress. Amsterdam, NL.
2013. Discussant for the session, "Dynamic Treatment Regimes & Adaptive Designs Toward Personalized Health Care". Invited. 2013 Joint Statistical Conference. Montreal, CA.
2013. Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy. Invited. 34th Annual Conference of the International Society for Clinical Biostatistics (ISCB). Munich, DE.
2013. Discussant, Dynamic Treatment Regimes and Adaptive Designs Toward Personalized Health Care. Invited. 2013 Joint Statistical Meeting. Montreal, CA.
2011. Establishing Priors from Elicited Values for Bayesian Dose-Finding Designs. Invited. Second Workshop, Continual Reassessment Method and Related Issues in Dose-Finding. Paris, FR.
2011. Optimizing the Bolus and Concentration of a Drug Administered by Continuous Infusion. Design of Experiments in Healthcare. Invited. Isaac Newton Institute for Mathematical Sciences. Cambridge, GB.
2010. A Hybrid Geometric Select-and-Test Design Based on Treatment Failure Time and Toxicity. Invited. Joint Statistical Meetings. Vancouver, CA.
2008. Two-Stage Treatment Strategies Based On Sequential Failure Times. Designed Experiments: Recent Advances in Methods and Applications. Invited. DEMA2008, Isaac Newton Institute for Mathematical Sciences. Cambridge, GB.
2008. Patient-Specific Dose-Finding Based On Bivariate Outcomes and Covariates. Session on "Bayesian Analysis of Pharmaceutical Data". Invited. International Society For Biopharmaceutical Statistics, First Symposium. Shanghai, CN.
2008. Comparing Two-Stage Treatment Strategies Based On Sequential Failure Times. Session on "Survival Analysis". Invited. International Society For Biopharmaceutical Statistics, First Symposium. Shanghai, CN.
2007. Innovative Bayesian Designs for Early Phase Clinical Trials. Invited. Third Strategic Directions in Cancer Therapy. Vancouver, CA.
2006. Practical Adaptive Randomization in Clinical Trials, Journee des Statisticiens des Centres de Lutte contre le Cancer. Invited. Institut Bergonie Annual Meeting. Bordeaux, FR.
2005. Dose Finding Based on Efficacy and Toxicity in Phase I/II Clinical Trials. Invited. 5th International Meeting on Statistical Methods in Biopharmacy, "Statistic Innovations in Clinical Trials". Paris, FR.
2004. Practical Hybrid Clinical Trial Designs, Session on Clinical trial designs to combine different stages of drug development. Invited. International Society for Clinical Biostatistics 25th Annual Conference. Leiden, NL.
2004. Hybrid Adaptive Designs for Clinical Trials, Session on Flexible Adaptive Designs. Invited. Joint Statistical Meetings. Toronto, CA.
2003. Adaptive Randomization in a Multi-Stage Trial: Gemcitabine +/- Docetaxel for Soft Tissue Sarcoma. Invited. In Session "Clinical Trials: 2003 and Beyond", Annual Meeting. Barcelona, ES.
2001. Practical Adaptive Sequential Dose-Finding in Phase I/II Clinical Trials. Invited. Statistics of Optimal Dosing, Henry Stewart Conferences. Washington, US.
2000. Approximate Bayesian Evaluation of Multiple Treatment Effects: An Alternative to Hypothesis Testing. Invited. Medical Statistics: Current Developments in Statistical Methodology for Clinical Trials. Oberwolfach, DE.
1999. Treatment Comparisons Based on Two-Dimensional Safety and Efficacy Alternatives in Oncology Trials. Invited. Region Oesterreich-Schweiz, Advances in Biometry. Basel, CH.
1997. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. Symposium on Treatment Selection in Early Phase Clinical Research, MPS Research Unit. Reading, GB.
1997. A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials. Invited. 3rd International Congress on Statistical Methods in Biopharmacy: Optimizing in Drug Development. Paris, FR.
1994. Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes. Invited. International Society of Clinical Biostatistics (ISCB) 15th Annual Meeting. Basel, CH.
1993. Bayesian Designs for Phase II Clinical Trials with Single or Multiple Endpoints. Invited. International Society of Clinical Biostatistics 14th Annual Meeting. Cambridge, GB.
1992. Bayesian Design and Monitoring of Phase II Clinical Trials. Invited. International Biometrics Conference. Hamilton, NZ.
1992. A Bayesian Strategy for Screening Cancer Treatments Prior to Phase II Clinical Evaluation. Invited. International Society of Clinical Statistics 13th Annual Meeting. Copenhagen, DK.
1992. Test-based Variable Selection via Cross-Validation. Conference. Baylor University. Waco, US.
1986. Nonparametric Two-Sample Tests for Recurrence Rates Based on Censored Count Data. Invited. Society for Clinical Trials Meeting. Montreal, CA.

Less

Grant & Contract Support

Date:	2027 - 2032
Title:	A Randomized Phase II Trial of MRD-Guided versus Uniform Post-Transplant Maintenance Therapy in High-Risk AML and MDS
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA323415-01

Date:	2027 - 2032
Title:	Novel Cord Blood Cellular Therapies/ADMIN CORE
Funding Source:	NIH
Role:	Key
ID:	2P01CA148600-12A

Date:	2026 - 2031
Title:	Illuminating the Immune Dynamics of Metastatic Renal Cell Carcinoma to Bone
Funding Source:	NIH
Role:	Co-PI
ID:	1R01CA307210-01A1

Date:	2026 - 2031
Title:	The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
Funding Source:	NIH
Role:	Key
ID:	P30CA016672-50

Date:	2026 - 2028
Title:	Optimal Learning from SMARTs with Complex Patient-Centered Outcomes
Funding Source:	University of Rochester
Role:	PI
ID:	#TBA

Date:	2025 - 2030
Title:	Development of Novel Engineered NK Cell Therapies for Relapsed or Refractory AML
Funding Source:	NATIONAL CANCER INSTITUTE
Role:	Co-I
ID:	#TBA

Date:	2025 - 2028
Title:	Prediction of benefit and toxicity associated with immunotherapy across various tumor types: development of tumor agnostic biomarkers
Funding Source:	US FOOD AND DRUG ADMINISTRATION
Role:	Co-I

Date:	2025 - 2030
Title:	Methadone versus short/intermediate acting opioids for the prevention of postmastectomy pain syndrome
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2027
Title:	Immune Modulating Effects of COVID-mRNA in Patients with Esophageal Cancer
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Collaborator
ID:	1R21CA299250-01

Date:	2025 - 2030
Title:	Dissecting the Effects of Radium 223 on Bone Health
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Collaborator
ID:	R01 AR083356-01A1

Date:	2025 - 2030
Title:	Combining Anti-Angiogenesis and Immunotherapy to Eradicate Bone Metastatic Renal Cell Carcinoma
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Collaborator
ID:	R01CA291924-01A1

Date:	2025 - 2030
Title:	Development of Novel Engineered NK Cell Therapies for Relapsed or Refractory AML
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Co-I
ID:	#TBA

Date:	2025 - 2026
Title:	Novel designs for multi-arm multi-dose multi-stage platform trials
Funding Source:	NIH
Role:	Key
ID:	1R21LM014699

Date:	2024 - 2026
Title:	Enhancement of high-dose chemotherapy for refractory lymphomas through PARP inhibition
Funding Source:	NATIONAL INSTITUTES OF HEALTH
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Methadone versus short/intermediate acting opioids for total mastectomy: MeCANO
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	SPORE University of Texas M.D. Anderson Cancer Center-Leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Transplantation of T and B cell depleted lung cells for the treatment of IPF patients
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R61HL174414-01

Date:	2024 - 2029
Title:	Combining Anti-Angiogenesis and Immunotherapy to Eradicate Bone Metastatic Renal Cell Carcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R01-CA291924-01

Date:	2024 - 2029
Title:	Dissecting the Effects of Radium 223 on Bone Health
Funding Source:	NIH/NIAMSD
Role:	Biostatistician
ID:	#TBA

Date:	2024 - 2027
Title:	Pharmacologic Pretransplant Immunosuppression (PRIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Funding Source:	DKMS Stiftung Leben Spenden
Role:	Statistician
ID:	#TBA

Date:	2024 - 2031
Title:	BMT Core- University of Texas, MD Anderson Cancer
Funding Source:	NIH/NCI
Role:	Other Significant Contributor
ID:	#TBA

Date:	2024 - 2029
Title:	Transplantation of T and B cell depleted lung cells for the treatment of IPF patients
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	Ex Vivo Engineering of Platelets and platelet progenitor cells from cord blood for the treatment of thrombocytopenia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2 R01CA061508-26

Date:	2023 - 2028
Title:	Dissect and improve anti-VEGF treatments to eradicate bone metastatic renal cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA285542-01

Date:	2023 - 2028
Title:	SPORE University of Texas M.D. Anderson Cancer Center-Leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2P50CA100632-21

Date:	2023 - 2028
Title:	Dissecting the Effects of 223 Radium on Bone Health
Funding Source:	NIH/NIAMS
Role:	Co-I
ID:	1R01AR083356-01

Date:	2023 - 2028
Title:	SPORE University of Texas M.D. Anderson Cancer Center-Leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2023 - 2026
Title:	CD70 Chimeric Antigen Receptor Natural Killer Cells in the Treatment of Relapsed/Refractory Multiple Myeloma
Funding Source:	CONQUER CANCER FOUNDATION
Role:	Biostatistician
ID:	ASCO CD70

Date:	2023 - 2026
Title:	Pretransplant immunosuppression (PTIS) with reduced toxicity SCT and PTCy for patients with inherited blood disorders
Funding Source:	DKMS Stiftung Leben Spenden
Role:	Statistician
ID:	#TBA

Date:	2023 - 2028
Title:	Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA280827-01

Date:	2023 - 2028
Title:	Combining Anti-Angiogenesis and Cell-based Immunotherapy to Eradicate Metastatic Renal Cell Carcinoma to Bone
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA272503-01A1

Date:	2023 - 2026
Title:	Overcoming therapy resistance by integrated computational modeling of the bone metastatic niche in prostate and renal cancers
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Biostatistician
ID:	RP230160

Date:	2022 - 2027
Title:	Translating FLASH Radiobiological Insights to Cutaneous Malignancies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA276160-01

Date:	2022 - 2027
Title:	MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source:	NIH/NCI
Role:	C1 Co-Investigator
ID:	2P50CA140388-11

Date:	2022 - 2027
Title:	Tissue-Engineered Models of Metastatic Prostate Cancer to Bone to Dissect and Overcome Therapy Resistance
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA262204-01A1

Date:	2022 - 2027
Title:	MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source:	NIH/NCI
Role:	C1 Co-Investigator
ID:	2P50CA140388-11A1

Date:	2022 - 2027
Title:	Combining Anti-Angiogenesis and Cell-based Immunotherapy to Eradicate Metastatic Renal Cell Carcinoma to Bone
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA272503-01

Date:	2022 - 2027
Title:	CD70 targeting cord blood derived NK cells for the treatment of relapsed refractory AML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA270698-01

Date:	2021 - 2025
Title:	Bayesian Methods for Complex Precision Biotherapy Trials in Oncology
Funding Source:	NIH/NCI
Role:	PD/PI
ID:	5R01CA261978-02

Date:	2021 - 2026
Title:	Tissue-engineered bone models of metastasis for organotypic cancer growth of patient-derived cells and personalized medicine
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA251693-01A1

Date:	2021 - 2026
Title:	Tissue-Engineered Models of Metastatic Prostate Cancer to Bone for Preclinical Analysis and Individualized Medicine
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA262204-01

Date:	2021 - 2024
Title:	PC200183: Tissue-Engineered Models of Bone Metastasis for Preclinical Analysis and Individualized Medicine
Funding Source:	Department of Defense (DOD)
Role:	Biostatistician
ID:	#TBA

Date:	2020 - 2022
Title:	The role of radiation therapy in sentinel lymph node positive melanoma
Funding Source:	Melanoma Research Foundation
Role:	Statistician
ID:	#TBA

Date:	2020 - 2025
Title:	Tissue-engineered bone models of metastasis for organotypic cancer growth of patient-derived cells and personalized medicine
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA251693-01

Date:	2020 - 2022
Title:	Tissue-engineered models of bone metastasis for preclinical analysis and individualized medicine
Funding Source:	Prostate Cancer Foundation
Role:	Collaborator
ID:	#TBA

Date:	2020 - 2025
Title:	Establishment of Translational Microbiome Core Services
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP200591

Date:	2020 - 2025
Title:	Clinical trial of microbiome optimization as prophylaxis for acute graft-versus-host disease
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA251810-01

Date:	2020 - 2023
Title:	The role of radiation therapy in sentinel lymph node positive melanoma
Funding Source:	Melanoma Research Alliance
Role:	Statistician
ID:	#TBA

Date:	2020 - 2021
Title:	Adjuvant radiation therapy for sentinel lymph node positive melanoma
Funding Source:	UTMDACC Melanoma SPORE CEP Award
Role:	Statistician
ID:	5P50CA221703

Date:	2020 - 2025
Title:	Hybrid Multiphase Designs for Treatment Refinement and Evaluation
Funding Source:	LSUHSC School of Public Health - New Orleans
Role:	Co-I
ID:	FP00008167

Date:	2019 - 2023
Title:	Clinical trial of microbiome optimization as prophylaxis for acute graft-versus-host disease
Funding Source:	Food and Drug Administration (FDA)
Role:	Co-I
ID:	1R01D006838-01

Date:	2019 - 2026
Title:	Cancer Center Support Grant (CCSG) - Biostatistics Resource Group (BRG)
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	5 P30 CA016672 47

Date:	2019 - 2022
Title:	CIS checkpoint deletion in cord blood derived iC9.CAR19.IL-15 NK cells for the treatment of B-cell hematologic malignancies
Funding Source:	DKMS Stiftung Leben Spenden
Role:	Co-I
ID:	MKMS-SLS-MHG-2019-01

Date:	2019 - 2020
Title:	Treatment of Multiple Myeloma with CAR-NK and TIGIT blockade
Funding Source:	Conquer Cancer Foundation
Role:	Biostatistician
ID:	FP00006446

Date:	2019 - 2020
Title:	CIS checkpoint deletion in cord blood derived iC9.CAR19.IL-15 NK cells to treat B-cell hematologic malignancies
Funding Source:	Society for Immunotherapy of Cancer
Role:	Co-I
ID:	FP00008548

Date:	2019 - 2022
Title:	Bayesian Feature Allocation Models for Cellular Phenotypic and Functional Analysis Using CyTOF Data
Funding Source:	National Science Foundation (NSF)
Role:	PD/PI
ID:	FP00007314

Date:	2019 - 2024
Title:	Statistical Methods for Complex Cancer Trials
Funding Source:	NIH/NCI
Role:	PI
ID:	2R01CA083932-17A1

Date:	2019 - 2023
Title:	An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy with a Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00002764_Res1

Date:	2018 - 2023
Title:	Clinical Trial of Targeting the Microbiome to Reduce Acute Intestinal GVHD
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01HL141883-01A1

Date:	2018 - 2023
Title:	IL15-Secreting Armored CAR-NK cells Targeting CD19+ Cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA235614-01

Date:	2018 - 2022
Title:	Improving the Efficacy of Chimeric Antigen Receptor Cellular Therapy for Diffuse Large B-Cell Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180737

Date:	2018 - 2023
Title:	Statistical Methods for Complex Cancer Trials
Funding Source:	NIH
Role:	PD/PI
ID:	2R01CA083932 17

Date:	2018 - 2023
Title:	Precision High-Dose Chemotherapy for Diffuse Large B-Cell Lymphoma
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA225976-01

Date:	2018 - 2023
Title:	Engineering Cord Blood NK cells as an off-the-shelf source of Cellular Therapy for B-lymphoid Malignancies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA225828-01

Date:	2018 - 2022
Title:	An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy with a Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180523

Date:	2018 - 2021
Title:	Improving the efficacy of chimeric antigen receptor cellular therapy for diffuse large B-cell Lymphoma
Funding Source:	Multidisciplinary Research Advisory Committee
Role:	Co-I

Date:	2017 - 2020
Title:	Fast Track: An Adaptive Phase I/II Dose Escalation Trial of Sterotactic Body Radiation Therapy in Combination with Radiomodulating Agent GC4419 in Locally Advanced Pancreatic AdenoCarcinoma
Funding Source:	Galera Therapeutics, Inc
Role:	Biostatistician
ID:	CS2017-00054748-LG

Date:	2017 - 2020
Title:	Immunotherapy for Multiple Myeloma Using Off-the-Shelf Cord Blood Derived NK Cells
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I
ID:	6555-18

Date:	2017 - 2021
Title:	T-Regulatory Cells TREGs derived from umbilical cord blood
Funding Source:	Cellenkos
Role:	Biostatistician
ID:	54964

Date:	2017 - 2019
Title:	Imaging & Serum Biomarkers for Detection of Cardiac Injury from Radiotherapy
Funding Source:	NIH
Role:	Co-I
ID:	1R21CA223780-01

Date:	2017 - 2022
Title:	Novel Cord Blood Derived Cellular Therapies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2P01CA148600-07

Date:	2017 - 2018
Title:	Impact of minimal residual disease in predicting outcomes of myeloma patients undergoing autologous stem cell transplant
Funding Source:	YIA Conquer Cancer Foundation
Role:	Biostatistician
ID:	FP00000093

Date:	2016 - 2022
Title:	Off-the-shelf engineered NK cells for the treatment of AML
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5R01CA211044-05

Date:	2016 - 2023
Title:	MD Anderson Cancer Center Prostate Cancer SPORE Core 2: Biostatistics and Bioinformatics
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P50CA140388-10

Date:	2016 - 2017
Title:	High-Risk Multiple Myeloma Moon Shot Flagship 2
Funding Source:	MDACC
Role:	Co-I
ID:	710499-80-116532-21

Date:	2016 - 2024
Title:	Hematopoietic Progenitor Cells - Cord Blood
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA061508-25

Date:	2015 - 2020
Title:	The role of regulatory B cells in tumor immune escape
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA201597-01

Date:	2015 - 2016
Title:	Hematopoietic Progenitor Cells - Cord Blood
Funding Source:	NIH/NCE
Role:	Co-I
ID:	5 R01 CA061508 20

Date:	2014 - 2019
Title:	Augmenting NK Cell Anti-Leukemic Activity in Haploidentical Stem Cell Transplants
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA184842 01

Date:	2014 - 2019
Title:	A Data Management Center for the National Stroke Trials Network
Funding Source:	NIH/NINDS (Subcontract from Columbia University)
Role:	Co-I
ID:	U01

Date:	2013 - 2017
Title:	Graft Engineering in Cord Blood Transplantation and Immune Recovery
Funding Source:	National Heart, Lung, and Blood Institute
Role:	Biostatistician
ID:	1R01HL122190-01

Date:	2013 - 2019
Title:	Statistical Methods for Complex Cancer Trials
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01CA083932 16

Date:	2013 - 2016
Title:	Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy
Funding Source:	American Association for Cancer Research (AACR)
Role:	Co-I
ID:	SUC2CR-AACR-DT10

Date:	2012 - 2014
Title:	Improving Response Assessments in Personalized Therapy for Pediatric Brain Tumors
Funding Source:	NIH/NCI (Subcontract from Tufts Medical Center)
Role:	Biostatistician
ID:	1 R21CA173224 01

Date:	2011 - 2023
Title:	Novel Cord Blood-Derived Cellular Therapies
Funding Source:	NIH/NCI
Role:	Core B Director
ID:	5P01CA148600-11

Date:	2011 - 2018
Title:	Improving Cord Blood Transplantation (Core B-Biostatistics)
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	4P01 CA148600 06

Date:	2011 - 2015
Title:	Transduction of T cells to improve migration to tumor
Funding Source:	NIH/NCI
Role:	Statistician
ID:	5 R01 CA116206 10

Date:	2011 - 2015
Title:	Adoptive Immunotherapy With NK Cells Expanded Ex Vivo For Treatment of Hematopoietic Malignancies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT) (Subaward from Baylor College of Medicine)
Role:	Collaborator
ID:	RP110553-P3

Date:	2011 - 2014
Title:	Clinical Core MIRA - Cellular Therapy for Cancer
Funding Source:	CPRIT (Subcontract from Baylor College of Medicine)
Role:	Co-I
ID:	RP110553-C1

Date:	2011 - 2013
Title:	Concurrent Azacitidine and Carboplatin for Castrate-Resistant Prostate Cancer
Funding Source:	NIH/NCI
Role:	Statistician
ID:	1 R21 CA159269 01

Date:	2011 - 2016
Title:	Cellular Therapy for Cancer – Clinical Research Core
Funding Source:	Other CPRIT Subcontract from Baylor College of Medicine
Role:	Biostatistician
ID:	n/a

Date:	2010 - 2016
Title:	Therapy of CML - Biostatistics Core (PC-B)
Funding Source:	NIH/NCI
Role:	Core Director
ID:	5 P01 CA049639 24

Date:	2010 - 2013
Title:	Targeting hypoxic bone marrow microenvironment in Acute Myeloid Leukemia (AML)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R21 CA153019 02

Date:	2010 - 2013
Title:	Translating Basic Science Discoveries into New and Better Treatments
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 RC4 CA156396 01

Date:	2010 - 2015
Title:	Choroid Plexus Tumor Treatment
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1 R01 CA151854 01

Date:	2010 - 2015
Title:	Hematopoietic Progenitor Cells - Cord Blood
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R01 CA061508 18

Date:	2010 - 2012
Title:	Targeting Therapy to Tumor Markers in Pediatric Brain Tumors, Proof of Principle
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1 R21 CA149900 01

Date:	2009 - 2014
Title:	MD Anderson Cancer Center Prostate SPORE (PC-B)
Funding Source:	NIH/NCI
Role:	Investigator
ID:	5 P50 CA140388 05

Date:	2009 - 2011
Title:	Personalized targeted therapy for refractory pediatric brain tumors
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1 RC1 CA147267 01

Date:	2009 - 2011
Title:	Enhancing the efficacy of androgen ablation in advanced prostate cancer by Hedgeh
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1 RC1 CA146956 01

Date:	2009 - 2013
Title:	Statistical Methods for Complex Cancer Trials
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R01 CA083932 11

Date:	2008 - 2012
Title:	Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity (PC-C)
Funding Source:	NIH/NCI
Role:	Core Director, Core C
ID:	5 P01 CA128913 04

Date:	2005 - 2010
Title:	New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (PC-C)
Funding Source:	NIH/NCI
Role:	Consult
ID:	5 P01 CA108631 05

Date:	2004 - 2007
Title:	A Novel Autotransplant Protocol for CML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R21 CA108137 02

Date:	2003 - 2009
Title:	Rebuilding Immunity for Survival - Biostatistics Core (PC-D)
Funding Source:	NIH/NCI
Role:	Biostatistics Core Leader
ID:	5 U19 CA100265 05

Date:	2003 - 2006
Title:	Planning/Program of Excellence in Biomedical Computing
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 P20 CA094815 01A2

Date:	2003 - 2010
Title:	Hematopoietic Progenitor Cells
Funding Source:	NIH/NCI
Role:	Statistician
ID:	5 R01 CA061508 15

Date:	2001 - 2007
Title:	Immunotherapy of low risk myelodysplastic syndrome
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5 R01 CA085843 05

Date:	2000 - 2008
Title:	Statistical Methods for Complex Cancer Trials
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R01 CA083932 09

Date:	1997 - 2009
Title:	Therapy of CML (PP-2)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 P01 CA049639 19

Selected Publications

Peer-Reviewed Articles

Yang, CH, Thall, PF, Marin, D, Belay, SY, Lin, R. BAR12. Statistics in Medicine 45(8-9), 2026. e-Pub 2026. PMID: 42009580.
Yang, CH, Thall, PF, Lin, R. DEMO. Annals of Applied Statistics 19(4):2599-2617, 2025. e-Pub 2025.
Nieto Y, Ward JF, Hofstetter W, Rice D, Karam JA, Pisters L, Vauthey JN, Shah A, Lin JK, Johns AC, Araujo J, Tu SM, Wang J, Li J, Abudayyeh A, Thall PF, Bassett R, Barnett M, Gulbis A, Shigle TL, Ramdial J, Popat U, Qazilbash M, Jones RB, Andersson BS, Shpall EJ, Sheikh I, Pagliaro L, Campbell MT. HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORS. Clin Cancer Res 32(2):300-311, 2025. e-Pub 2025. PMID: 40853903.
Oran, B, Thall, PF, Alousi, AM, Al-Atrash, G, Mehta, RS, Marin, D, Kebriaei, P, Popat, UR, Bassett Jr, R, Bashir, Q, Im, JS, Olson, AL, Jewell, J, Smallbone, PI, Shpall, E, Champlin, RE. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant. Haematologica 111(1):149-157, 2025. e-Pub 2025. PMID: 40702903.
Zhao S, Thall PF, Yuan Y, Lee J, Msaouel P, Zang Y. Precision generalized phase I-II designs. Biometrics 81(3), 2025. e-Pub 2025. PMID: 40705487.
Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
Berg, S, La Rosa, S, Zhang, T, Pierorazio, P, Albiges, L, Beckermann, KE, Campbell, M, Carlo, MI, Coleman, K, George, DJ, Geynisman, DM, Johnson, R, Jonasch, E, Maranchie, J, McGregor, BA, Shapiro, DD, Singer, EA, Shuch, B, Stadler, WM, Tannir, NM, Zakharia, Y, Vaishampayan, U, Thall, PF, Msaouel, P. Impact of post-progression therapies on overall survival. Urologic Oncology: Seminars and Original Investigations 43(3):135-146, 2025. e-Pub 2025. PMID: 39500687.
Lee, J, Thall, PF. Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility-Based Rule. Statistics in Medicine 43(29):5583-5595, 2024. e-Pub 2024. PMID: 39497640.
Wang, S, Thall, PF, Takeda, K, Yuan, Y. ROMI. Biometrics 80(4), 2024. e-Pub 2024. PMID: 39360905.
Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
Cata, JP, Zaidi, Y, Guerra-Londono, JJ, Kharasch, ED, Piotrowski, MJ, Kee, SS, Cortes-Mejia, NA, Gloria-Escobar, JM, Thall, PF, Lin, R. Intraoperative methadone administration for total mastectomy. Journal of Clinical Anesthesia 98, 2024. e-Pub 2024. PMID: 39180867.
Mitchell KG, Feldman H, Milton DR, Antonoff MB, Hofstetter WL, Rice DC, Vaporciyan AA, Lin R, Thall PF, Rajaram R, Study Group AOMOTMACCEA. Signet ring cells and conditional survival after trimodality therapy for esophageal adenocarcinoma. J Surg Oncol. e-Pub 2024. PMID: 39004940.
Yang X, Cheng Y, Thall PF, Wahed AS. A generalized outcome-adaptive sequential multiple assignment randomized trial design. Biometrics 80(3), 2024. e-Pub 2024. PMID: 39106124.
Msaouel, P, Lee, J, Thall, PF. Risk–benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical Trials 21(3):287-297, 2024. e-Pub 2024. PMID: 38111231.
Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80(1), 2024. e-Pub 2024. PMID: 38364811.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. e-Pub 2024. PMID: 38238616.
Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MHG, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol 24(12):1387-1398, 2023. e-Pub 2023. PMID: 38039992.
Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani K. Ex vivo-expanded cord blood NK cells combined with rituximab and high dose chemotherapy with autologous sct for B-NHL. Transplant Cell Ther 01709-8(23):2666-6367. e-Pub 2023. PMID: 38042257.
Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clin Trials 20(5):486-496, 2023. e-Pub 2023. PMID: 37313712.
Lee J, Thall PF, Msaouel P. Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity. Biometrics 79(3):2458-2473, 2023. e-Pub 2023. PMID: 35974457.
Gladstone DE, D'Alessio F, Howard C, Lyu MA, Mock JR, Gibbs KW, Abrams D, Huang M, Zeng K, Herlihy JP, Castillo ST, Bassett R, Sadeghi T, Parmar S, Flowers CR, Mukherjee S, Schoenfeld D, Thall PF, Slutsky AS. Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS. Blood Adv 7(13):3075-3079, 2023. e-Pub 2023. PMID: 36961352.
Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 7(30):100514, 2023. e-Pub 2023. PMID: 35051703.
Lui A, Lee J, Thall PF, Daher M, Rezvani K, Basar R. A Bayesian feature allocation model for identifying cell subpopulations using CyTOF data. J R Stat Soc Ser C Appl Stat 72(3):718-738, 2023. e-Pub 2023. PMID: 37325776.
Qing Y, Thall PF, Yuan Y. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharm Stat 22(1):34-44, 2023. e-Pub 2023. PMID: 35851545.
Thall PF, Zang Y, Yuan Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharm Stat 22(4):692-706, 2023. e-Pub 2023. PMID: 37038957.
McGovern SL, Luo D, Johnson J, Nguyen K, Li J, McAleer MF, Yeboa D, Grosshans DR, Ghia AJ, Chung C, Bishop AJ, Song J, Thall PF, Brown PD, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Adults. Pract Radiat Oncol 13(3):231-238, 2023. e-Pub 2023. PMID: 36596356.
Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. Bayesian hierarchical random-effects meta-analysis and design if Phase I clinical trials. Ann Appl Stat 16(4):2481-2504, 2022. e-Pub 2022. PMID: 36329718.
Lee, J, Thall, PF, Lim, B, Msaouel, P. Utility-based Bayesian personalized treatment selection for advanced breast cancer. Journal of the Royal Statistical Society. Series C: Applied Statistics 71(5):1605-1622, 2022. e-Pub 2022. PMID: 36714159.
Andersson BS, Thall PF, Ma J, Valdez BC, Jr BR, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
Park Y, Liu S, Thall PF, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics 78(1):60-71, 2022. e-Pub 2022. PMID: 33438761.
Rice D, Rodriguez-Restrepo A, Mena G, Cata J, Thall P, Milton D, Correa A, Woodard T, Antonoff M, Hofstetter W, Roth J, Sepesi B, Swisher S, Walsh G, Vaporciyan A, Mehran R. Matched pairs comparison of an enhanced recovery pathway versus conventional management on opioid exposure and pain control in patients undergoing lung surgery. Ann Surg 274(6):1099-1106, 2021. e-Pub 2021. PMID: 32229762.
Ghia A, Guha-Thakurta N, Song J, Thall PF, et al. Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously irradiated metastatic epidural spinal cord compression. North American Spine Soc J, 2021. e-Pub 2021.
Ghia AJ, Guha-Thakurta N, Song J, Thall P, Briere TM, Settle SH, Sharp HJ, Li J, McAleer M, Chang EL, Tatsui CE, Brown PD, Rhines LD. Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously irradiated metastatic epidural spinal cord compression. N Am Spine Soc J 6:100066, 2021. e-Pub 2021. PMID: 35141631.
Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol, 2021. e-Pub 2021. PMID: 33995420.
Lin R, Thall PF, Yuan Y. A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes. Bayesian Anal 16(1):179-202, 2021. e-Pub 2021. PMID: 34267857.
Thall PF. Adaptive Enrichment Designs in Clinical Trials. Annu Rev Stat Appl 8(1):393-411, 2021. e-Pub 2021. PMID: 36212769.
Dahlstrom KR, Song J, Thall PF, Fuller CD, Hutcheson KA, Johnson FM, Gunn GB, Phan J, Frank SJ, Morrison WH, Ferrarotto R, Rosenthal DI, Sturgis EM, Garden AS. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer 127(8):1228-1237, 2021. e-Pub 2021. PMID: 33306202.
Murray TA, Thall PF, Schortgen F, Zohar S, Asfar P, Katsahian S. Robust adaptive incorporation of historical control data in design of a randomized controlled trial to evaluate external cooling in treatment of septic shock. Bayesian Analysis 16:825-844, 2021. e-Pub 2021.
Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc 116(533):322-334, 2021. e-Pub 2021. PMID: 35582047.
Tidwell RSS, Thall PF, Yuan Y. Lessons learned from implementing a novel Bayesian adaptive dose-finding design in advanced pancreatic cancer. JCO Precis Oncol 5:1719-1726, 2021. e-Pub 2021. PMID: 34805718.
Lee J, Thall PF, Msaouel P. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Stat Med 40(24):5199-5217, 2021. e-Pub 2021. PMID: 34636054.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39:2710-2719, 2021. e-Pub 2021. PMID: 33929874.
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
Jiang L, Yan F, Thall PF, Huang X. Comparing Bayesian early stopping boundaries for phase II clinical trials. Pharm Stat 19(6):928-939, 2020. e-Pub 2020. PMID: 32720462.
Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, Mandrekar SJ. Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials. Cancers (Basel) 12(11):3251, 2020. e-Pub 2020. PMID: 33158080.
Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
Chapple AG, Thall PF. Comparison of phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteria. Contemporary Clinical Trials. 97, 2020. e-Pub 2020.
Diao K, Song J, Thall PF, McGinnis GJ, Boyce-Fappiano D, Amini B, Brown PD, Yeboa DN, Bishop AJ, Li J, Briere TM, Tatsui CE, Rhines LD, Chang EL, Ghia AJ. Low risk of radiation myelopathy with relaxed spinal cord dose constraints in de novo, single fraction spine stereotactic radiosurgery. Radiother Oncol 152:49-55, 2020. e-Pub 2020. PMID: 32745668.
Oran B, de lima M, Garcia-Manero G, Thall PF, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high risk AML/MDS patients. Blood Advances 4:5580-5588, 2020. e-Pub 2020.
Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76:304-315, 2020. e-Pub 2020. PMID: 31273750.
Liu E, Marin D, Banerjee P, Macapinlac H, Thall PF, Rezvani K, et al. IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors. New England Journal of Medicine 382:545-553, 2020. e-Pub 2020.
Lee J, Thall PF, Msaouel P. A phase I-II design based on periodic and continuous monitoring of ordinal disease severity and the times to toxicity and death. Statistics in Medicine 39:2035-2050, 2020. e-Pub 2020.
Aparicio A, Thall P, Logothetis C. Radiotherapy for metastatic prostate cancer. Lancet 394(10201):829-830, 2019. e-Pub 2019. PMID: 31498098.
Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant 54(8):1245-1253, 2019. e-Pub 2019. PMID: 30532055.
Chapple AG, Thall PF. A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III. Biometrics 75(2):371-381; (Discussion 382-388, Rejoinder 389-391), 2019. e-Pub 2019. PMID: 30367457.
Chapple AG, Thall PF. Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III". Biometrics 75(2):389-391, 2019. e-Pub 2019. PMID: 31245839.
Boulet S, Ursino M, Thall P, Jannot AS, Zohar S. Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer. Stat Med 38(12):2228-2247, 2019. e-Pub 2019. PMID: 30672015.
Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL. A Phase I/II Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys 104(1):144-148, 2019. e-Pub 2019. PMID: 30610915.
Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
Boulet S, Ursino M, Thall P, Landi B, Lepère C, Pernot S, Burgun A, Taieb J, Zaanan A, Zohar S, Jannot AS. Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. Stat Methods Med Res:962280219841082. e-Pub 2019. PMID: 30963815.
Xu Y, Thall PF, Hua W, Andersson BS. Bayesian nonparametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. J R Stat Soc Ser C Appl Stat 68(3):809-828, 2019. e-Pub 2019. PMID: 31467455.
Lee J, Thall PF, Lin SH. Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer Patients. Ann Appl Stat 13(1):221-247, 2019. e-Pub 2019. PMID: 31681453.
Lee J, Thall PF, Rezvani K. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times. J R Stat Soc Ser C Appl Stat 68(2):461-474, 2019. e-Pub 2019. PMID: 31105345.
Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60:442-452, 2019. e-Pub 2019. PMID: 30032678.
Thall PF, Ursino M, Baudouin V, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Stat Methods Med Res 28:404-418, 2019. e-Pub 2019. PMID: 28870123.
Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget 9(86):35611-35622, 2018. e-Pub 2018. PMID: 30479692.
Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res 24(17):4098-4109, 2018. e-Pub 2018. PMID: 29769208.
Chapple AG, Thall PF. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination. Pharm Stat. e-Pub 2018. PMID: 30112806.
Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding with novel agents. Ann Oncol 29(3):694-699, 2018. e-Pub 2018. PMID: 29267863.
Murray TA, Yuan Y, Thall PF. A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. J Am Stat Assoc 113(523):1255-1267, 2018. e-Pub 2018. PMID: 30739965.
Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103, 2018. e-Pub 2018. PMID: 29359314.
Wathen JK, Thall PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clin Trials 14(5):432-440, 2017. e-Pub 2017. PMID: 28982263.
Chapple AG, Vannucci M, Thall PF, Lin SH. Bayesian variable selection for a semi-competing risks model with three hazard functions. Computational Statistics and Data Analysis 112:170-185, 2017. e-Pub 2017. PMID: 29033478.
Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol 123(3):376-381, 2017. e-Pub 2017. PMID: 28455153.
Andersson BS, Thall PF, et al. Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
Morita S, Thall PF, Takeda K. A simulation study of methods for selecting subgroup-specific doses in phase 1 trials. Pharm Stat 16(2):143-156, 2017. e-Pub 2017. PMID: 28111916.
Xu Y, Thall PF, Müller P, Mehran RJ. A decision-theoretic comparison of treatments to resolve air leaks after lung surgery based on nonparametric modeling. Bayesian Anal 12(3):639-652, 2017. e-Pub 2017. PMID: 28959372.
Thall PF, Nguyen HQ, Zinner RG. Parametric dose standardization for two-agent combinations in a phase I-II trial with ordinal outcomes. J Royal Statistical Society, Series C (Applied Statistics) 66:201-224, 2017. e-Pub 2017. PMID: 28255183.
Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc 112:11-23, 2017. e-Pub 2017. PMID: 28943681.
Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31:697-704, 2017. e-Pub 2017. PMID: 27654852.
Thall PF, Mueller P, Xu Y, Guindani M. Bayesian nonparametric statistics: A new toolkit for discovery in cancer research. Pharm Stat 16:414-423, 2017. e-Pub 2017. PMID: 28677272.
Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22(10):1792-800, 2016. e-Pub 2016. PMID: 27377901.
Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Stat Med 35(24):4285-4305, 2016. e-Pub 2016. PMID: 27189672.
He L, Chapple A, Liao Z, Komaki R, Thall PF, Lin SH. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol 121(1):70-74, 2016. e-Pub 2016. PMID: 27562616.
Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-8, 2016. e-Pub 2016. PMID: 27203405.
Lee J, Thall PF, Ji Y, Müller P. A practical decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics 17(2):304-19, 2016. e-Pub 2016. PMID: 26553915.
Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat 65(2):273-297, 2016. e-Pub 2016. PMID: 27034510.
Xu Y, Müller P, Wahed AS, Thall PF. Bayesian nonparametric estimation for dynamic treatment regimes with sequential transition times (with discussion). J Am Stat Assoc 111(515):921-950, 2016. e-Pub 2016. PMID: 28018015.
Thall PF. Discussion on "Bayesian nonparametric estimation for dynamic treatment regimes with sequential transition times" by Xu Y, Mueller P, Wahed A, Thall PF 111:921-950, 2016. e-Pub 2016.
Huang X, Choi S, Wang L, Thall PF. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Stat Med 34(26):3424-43, 2015. e-Pub 2015. PMID: 26095711.
Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 2015. e-Pub 2015. PMID: 26071868.
Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer 121(20):3659-67, 2015. e-Pub 2015. PMID: 26177983.
Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. J Neurooncol 125(1):133-41, 2015. e-Pub 2015. PMID: 26255071.
Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29(9):1945-8, 2015. e-Pub 2015. PMID: 25721897.
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1392-8, 2015. e-Pub 2015. PMID: 25985919.
Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-46, 2015. e-Pub 2015. PMID: 25867648.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
Lee J, Thall PF, Ji Y, Müller P. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. J Am Stat Assoc 110(510):711-722, 2015. e-Pub 2015. PMID: 26366026.
Graziani R, Guindani M, Thall PF. Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome. Biometrics 71(1):188-97, 2015. e-Pub 2015. PMID: 25319212.
Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol 10(3):518-26, 2015. e-Pub 2015. PMID: 25695222.
Thall PF, Herrick RC, Nguyen HQ, Venier JJ, Norris JC. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials 11(6):657-66, 2014. e-Pub 2014. PMID: 25179541.
Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32(31):3497-505, 2014. e-Pub 2014. PMID: 25267759.
Wang L, Shen J, Thall PF. A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity Constraint. Stat Probab Lett 93:126-133, 2014. e-Pub 2014. PMID: 25071299.
Thall PF, Nguyen HQ, Zohar S, Maton P. Optimizing sedative dose in preterm infants undergoing treatment for respiratory distress syndrome. J Am Stat Assoc 109(507):931-943, 2014. e-Pub 2014. PMID: 25368435.
Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant 20(8):1139-44, 2014. e-Pub 2014. PMID: 24727332.
Jin IH, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. J Am Stat Assoc 109(506):525-536, 2014. e-Pub 2014. PMID: 25382884.
Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 24(11):2844-2849, 2013. e-Pub 2013. PMID: 23975663.
Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 69(3):673-682, 2013. e-Pub 2013. PMID: 23957592.
Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48(9):1218-23, 2013. e-Pub 2013. PMID: 23503529.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
David E, Thall PF, Kalhor N, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Wei C, Mehran RJ. Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg 95(6):1872-7, 2013. e-Pub 2013. PMID: 23643547.
Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study. Biol Blood Marrow Transplant 19(3):474-80, 2013. e-Pub 2013. PMID: 23220013.
Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
Wahed AS, Thall PF. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukemia. J R Stat Soc Ser C Appl Stat 62(1):67-83, 2013. e-Pub 2013. PMID: 24014891.
Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 84(5):1078-85, 2012. e-Pub 2012. PMID: 22867894.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
Morita S, Thall PF, Müller P. Prior effective sample size in conditionally independent hierarchical models. Bayesian Anal 7(3):591-614, 2012. e-Pub 2012. PMID: 24175005.
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 118(14):3549-55, 2012. e-Pub 2012. PMID: 22086552.
Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Rejoinder - Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc 107(498):518-420, 2012. e-Pub 2012. PMID: 24489418.
Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc 107(498):493-508, (with discussion, pages 509-517), 2012. e-Pub 2012. PMID: 22956855.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2012. PMID: 21887685.
Thall PF, Nguyen HQ, Wang X, Wolff JE. A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity. J Stat Plan Inference 142(4):944-955, 2012. e-Pub 2012. PMID: 22228921.
Yuan Y, Thall PF, Wolff JE. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. J R Stat Soc Ser C Appl Stat 61(1):135-149, 2012. e-Pub 2012. PMID: 22408277.
Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc 107(498):518-520, 2012. e-Pub 2012. PMID: 24489418.
Thall PF, Nguyen HQ. Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. J Biopharm Stat 22(4):785-801, 2012. e-Pub 2012. PMID: 22651115.
Thall PF, Szabo A, Nguyen HQ, Amlie-Lefond CM, Zaidat OO. Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics 67(4):1638-46, 2011. e-Pub 2011. PMID: 21401568.
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118(22):5957-64, 2011. e-Pub 2011. PMID: 21967975.
Thall PF, Liu DD, Berrak SG, Wolff JE. Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies. Stat Med 30(15):1777-94, 2011. e-Pub 2011. PMID: 21590700.
Mathew P, Wen S, Morita S, Thall PF. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. J Interferon Cytokine Res 31(7):539-44, 2011. e-Pub 2011. PMID: 21323568.
Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, Ketonen L, Kuttesch J, Liu D, Thall P, Chang EL. Induction treatment for diffuse intrinsic pontine glioma, experience of m.d. Anderson cancer center. Anticancer Res 31(6):2265-9, 2011. e-Pub 2011. PMID: 21737651.
Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 2011. e-Pub 2011. PMID: 20946966.
Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23):5420-31, 2010. e-Pub 2010. PMID: 20672358.
Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 28(24):3851-7, 2010. e-Pub 2010. PMID: 20625118.
Morita S, Thall PF, Müller P. Evaluating the impact of prior assumptions in Bayesian biostatistics. Stat Biosci 2(1):1-17, 2010. e-Pub 2010. PMID: 20668651.
Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A. Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics 66(2):532-40, 2010. e-Pub 2010. PMID: 19673865.
Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2010. e-Pub 2010. PMID: 20052721.
Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JE. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol 95(3):383-92, 2009. e-Pub 2009. PMID: 19543851.
Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15(11):1431-8, 2009. e-Pub 2009. PMID: 19822303.
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell transplantation. Transplantation 88(8):1019-24, 2009. e-Pub 2009. PMID: 19855248.
Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. J R Stat Soc Ser C Appl Stat 59(1):19-34, 2009. e-Pub 2009. PMID: 20390057.
Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592-7, 2009. e-Pub 2009. PMID: 19414678.
Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol 21 Suppl 1:S11-5, 2009. e-Pub 2009. PMID: 19561406.
McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A randomized phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 16(4):910-919, 2009. e-Pub 2009. PMID: 18953611.
Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. e-Pub 2009. PMID: 19244175.
Norman PH, Thall PF, Purugganan RV, Riedel BJ, Thakar DR, Rice DC, Huynh L, Qiao W, Wen S, Smythe WR. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer 115(4):833-841, 2009. e-Pub 2009. PMID: 19130460.
Thall PF. Discussion on "A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials" by Elena M. Buzaianu and Pinyuen Chen. Seq Anal 28(1):41-43, 2009. e-Pub 2009. PMID: 20622929.
Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 181(1):81-87, 2009. e-Pub 2009. PMID: 19012911.
Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics 64(4):1126-36, 2008. e-Pub 2008. PMID: 18355387.
Wathen JK, Thall PF. Bayesian adaptive model selection for optimizing group sequential clinical trials. Stat Med 27(27):5586-604, 2008. e-Pub 2008. PMID: 18752257.
Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer 99(9):1426-32, 2008. e-Pub 2008. PMID: 18841158.
Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 2008. e-Pub 2008. PMID: 18635226.
Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Stat Med 27(15):2802-15, 2008. e-Pub 2008. PMID: 17948869.
Whelan HT, Cook JD, Amlie-Lefond CM, Hovinga CA, Chan AK, Ichord RN, Deveber GA, Thall PF. Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children. Stroke 39(9):2627-36. e-Pub 2008. PMID: 18617665.
Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics 9(3):442-57, 2008. e-Pub 2008. PMID: 18084008.
Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-84, 2008. e-Pub 2008. PMID: 18489993.
Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics 64(2):595-602, 2008. e-Pub 2008. PMID: 17764481.
de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-264, 2008. e-Pub 2008. PMID: 17989720.
McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 13(22 Pt 1):6727-34, 2007. e-Pub 2007. PMID: 18006774.
Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 2007. e-Pub 2007. PMID: 17879948.
Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst 99(21):1613-22. e-Pub 2007. PMID: 17971530.
Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-24, 2007. e-Pub 2007. PMID: 17908974.
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 25(19):2755-63, 2007. e-Pub 2007. PMID: 17602081.
Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-4702, 2007. e-Pub 2007. PMID: 17427204.
Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials 4(2):113-124, 2007. e-Pub 2007. PMID: 17456511.
Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 106(7):1617-23, 2006. e-Pub 2006. PMID: 16518826.
Thall PF, Wooten LH, Shpall EJ. A geometric approach to comparing treatments for rapidly fatal diseases. Biometrics 62(1):193-201, 2006. e-Pub 2006. PMID: 16542246.
Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 2006. e-Pub 2006. PMID: 17029276.
Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med 25(1):55-70, 2006. e-Pub 2006. PMID: 16025549.
Braun TM, Yuan Z, Thall PF. Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics 61(2):335-43, 2005. e-Pub 2005. PMID: 16011679.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-14, 2005. e-Pub 2005. PMID: 15682071.
Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials 2(6):467-78, 2005. e-Pub 2005. PMID: 16422307.
Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Stat Med 24(13):1947-1964, 2005. e-Pub 2005. PMID: 15806621.
Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 22(22):4567-74, 2004. e-Pub 2004. PMID: 15542808.
Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60(3):684-93, 2004. e-Pub 2004. PMID: 15339291.
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857-64, 2004. e-Pub 2004. PMID: 15073038.
Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 22(16):3375-80, 2004. e-Pub 2004. PMID: 15310783.
Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22(16):3323-9, 2004. e-Pub 2004. PMID: 15310776.
Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 33(12):1191-9, 2004. e-Pub 2004. PMID: 15122310.
Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10(9):2968-76, 2004. e-Pub 2004. PMID: 15131032.
Bekele BN, Thall PF. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J American Statistical Assoc 99:26-35, 2004. e-Pub 2004.
Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood 102:3097-9, 2003. e-Pub 2003. PMID: 12842982.
Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in Phase I oncology trials. Biometrics 59:487-96, 2003. e-Pub 2003. PMID: 14601749.
Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 102:442-8, 2003. e-Pub 2003. PMID: 12560224.
Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 21:878-83, 2003. e-Pub 2003. PMID: 12610188.
Shaw PH, Gilligan D, Wang XM, Thall PF, Corey SJ. Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture system. Biol Blood Marrow Transplant 9:151-6, 2003. e-Pub 2003. PMID: 12652464.
Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 22:763-80, 2003. e-Pub 2003. PMID: 12587104.
Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1):73-9, 2003. e-Pub 2003. PMID: 12504632.
Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58:823-31, 2002. e-Pub 2002. PMID: 12495136.
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8:477-85, 2002. e-Pub 2002. PMID: 12374452.
Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics 58:560-8, 2002. e-Pub 2002. PMID: 12229990.
Thall PF, H-G S, Estey EH. Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials. J American Statistical Assoc 97:29-39, 2002. e-Pub 2002.
Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-65, 2002. e-Pub 2002. PMID: 12209719.
Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-80, 2002. e-Pub 2002. PMID: 12118020.
Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol 117(4):869-74, 2002. e-Pub 2002. PMID: 12060122.
Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99:4343-9, 2002. e-Pub 2002. PMID: 12036860.
Cheung YK, Thall PF. Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics 58:89-97, 2002. e-Pub 2002. PMID: 11890331.
Thall PF. Ethical issues in oncology biostatistics. Stat Methods Med Res 11(5):429-448, 2002. e-Pub 2002. PMID: 12357588.
Staniswalis JG, Thall PF. An explanation of generalized profile likelihoods. Statistics and Computing 11:293-298, 2001. e-Pub 2001.
Stallard N, Thall PF. Decision-theoretic designs for pre-phase II screening trials in oncology. Biometrics 57(4):1089-95, 2001. e-Pub 2001. PMID: 11764248.
Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98:3575-83, 2001. e-Pub 2001. PMID: 11739159.
Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92(9):2364-73, 2001. e-Pub 2001. PMID: 11745292.
Thall PF, Sung HG, Choudhury A. Dose-finding based on feasibility and toxicity in T-cell infusion trials. Biometrics 57(3):914-21, 2001. e-Pub 2001. PMID: 11550945.
Thall PF, Cheng SC. Optimal two-stage designs for clinical trials based on safety and efficacy. Stat Med 20(7):1023-32, 2001. e-Pub 2001. PMID: 11276033.
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631-7, 2001. e-Pub 2001. PMID: 11157478.
Thall PF. Bayesian clinical trial design in a cancer center. Chance 14:23-28, 2001. e-Pub 2001.
Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall PF, Siciliano MJ, Champlin RE. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol 18:1831-6, 2000. e-Pub 2000. PMID: 10784623.
Dougherty TB, Porche VH, Thall PF. Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia. Anesthesiology 92:1010-6, 2000. e-Pub 2000. PMID: 10754620.
Thall PF, Millikan RE, Sung HG. Evaluating multiple treatment courses in clinical trials. Stat Med 19:1011-28, 2000. e-Pub 2000. PMID: 10790677.
Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics 56:213-9, 2000. e-Pub 2000. PMID: 10783798.
Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95:72-7, 2000. e-Pub 2000. PMID: 10607687.
Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer 86:2291-300, 1999. e-Pub 1999. PMID: 10590370.
Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res 5:4041-7, 1999. e-Pub 1999. PMID: 10632337.
Thall PF, Estey EH, Sung HG. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Invest New Drugs 17(2):155-67, 1999. e-Pub 1999. PMID: 10638486.
Thall PF, Cheng SC. Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. Biometrics 55(3):746-53, 1999. e-Pub 1999. PMID: 11315002.
Thall PF, Lee JJ, C-H T, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. . Statistics in Medicine 18:1155-1169, 1999. e-Pub 1999. PMID: 10363337.
Stallard N, Thall PF, Whitehead J. Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics 55(3):971-7, 1999. e-Pub 1999. PMID: 11315037.
Albitar, Dong Q, Saunder D, Lucas L, Kaabi L, Zaldivar E, Thall PF. Evaluation of automated leukocyte differential counts in a cancer center. Laboratory Hematology 5:10-14, 1999. e-Pub 1999.
Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 5(7):1758-66, 1999. e-Pub 1999. PMID: 10430080.
Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia 13(6):850-4, 1999. e-Pub 1999. PMID: 10360371.
Przepiorka D, Khouri I, Thall PF, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Korbling M, Deisseroth AB, Champlin R. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 23:977-81, 1999. e-Pub 1999. PMID: 10373061.
Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8):2478-84, 1999. e-Pub 1999. PMID: 10194425.
Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92:3090-7, 1998. e-Pub 1998. PMID: 9787143.
Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med 158:876-84, 1998. e-Pub 1998. PMID: 9731020.
Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov Z. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma 30:583-9, 1998. e-Pub 1998. PMID: 9711920.
Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 17:1563-80, 1998. e-Pub 1998. PMID: 9699230.
Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med 17:999-1015, 1998. e-Pub 1998. PMID: 9612887.
Seong D, Thall PF, Kantarjian HM, Talpaz M, Swantkowski J, Xu J, Shen Y, Glassman A, Ramagli L, Siciliano MJ. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res 4:861-7, 1998. e-Pub 1998. PMID: 9563879.
Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54(1):251-64, 1998. e-Pub 1998. PMID: 9544520.
Thall PF, Russell KT, Simon RM. Variable selection in regression via repeated data splitting. J Computational and Graphical Stat 6:416-434, 1997. e-Pub 1997.
Staniswalis JG, Thall PF, Salch J. Semiparametric regression analysis for recurrent event interval counts. Biometrics 53:1334-53, 1997. e-Pub 1997. PMID: 9423253.
van Besien K, Thall PF, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 3:150-6, 1997. e-Pub 1997. PMID: 9310192.
Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall PF, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 19:455-60, 1997. e-Pub 1997. PMID: 9052911.
Estey EH, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483-90, 1997. e-Pub 1997. PMID: 9053469.
Estey EH, Thall PF, Pierce S, Kantarjian H, Keating M, Freireich E. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 11:1661-1664, 1997. e-Pub 1997. PMID: 9324286.
Estey EH, Thall PF, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90:2969-2977, 1997. e-Pub 1997. PMID: 9376577.
Estey EH, Thall PF, Mehta K, et al. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87:3650-3654, 1996. e-Pub 1996. PMID: 8611689.
Thall PF, Jacoby D, Zimmerman SO. Estimating genomic category probabilities from fluorescent in situ hybridization counts with misclassification. Applied Statistics 45:431-446, 1996. e-Pub 1996.
Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65-73, 1996. e-Pub 1996. PMID: 8699228.
Kornblau SM, Thall PF, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia 9:1735-41, 1995. e-Pub 1995. PMID: 7564518.
Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 33:357-64, 1995. e-Pub 1995. PMID: 7673023.
Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 14(4):357-379, 1995. e-Pub 1995. PMID: 7746977.
Thall PF, Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin Trials 15:463-81, 1994. e-Pub 1994. PMID: 7851108.
Estey Thall PF, et al. Use of G-CSF before, during, after fludarabine + ara-C induction therapy of newly-diagnosed AML or MDS: comparison with fludarabine + ara-C without G-CSF. J Clinical Oncology 12:671-678, 1994. e-Pub 1994. PMID: 7512125.
Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Stat Med 13:1727-36, 1994. e-Pub 1994. PMID: 7997706.
Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 50:337-49, 1994. e-Pub 1994. PMID: 7980801.
Thall PF, Estey EH. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat Med 12:1197-211, 1993. e-Pub 1993. PMID: 8210822.
Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246-55, 1992. e-Pub 1992. PMID: 1571541.
Thall PF, Simon R, Grier, DA. Test-based variable selection via cross-validation. J Computational and Graphical Statistics 1:41-61, 1992. e-Pub 1992.
Thall PF. Score tests in the two-way layout of counts. Communications in Statistics. Theory and Methods 21:3017-3036, 1992. e-Pub 1992.
Thall PF, Vail SC. Some covariance models for longitudinal count data with overdispersion. Biometrics 46:657-71, 1990. e-Pub 1990. PMID: 2242408.
Thall PF, Simon R. Incorporating historical control data in planning phase II clinical trials. Stat Med 9:215-28, 1990. e-Pub 1990. PMID: 2188324.
Halperin M, Hamdy MI, Thall PF. Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring. Biometrics 45:509-21, 1989. e-Pub 1989. PMID: 2765635.
Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45:537-47, 1989. e-Pub 1989. PMID: 2765637.
Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials. Biometrika 75:303-310, 1988. e-Pub 1988.
Thall PF, Simon R, Ellenberg SS, Shrager R. Optimal two-stage designs for clinical trials with binary response. Stat Med 71:571-579, 1988. e-Pub 1988. PMID: 3387716.
Thall PF. Mixed Poisson likelihood regression models for longitudinal interval count data. Biometrics 44:197-209, 1988. e-Pub 1988. PMID: 3358988.
Thall PF, Lachin JM. Analysis of recurrent events: nonparametric methods for random interval count data. J American Statistical Assoc 83:339-347, 1988. e-Pub 1988.
Thall PF, Lachin JM. Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Stat Med 5:73-83, 1986. e-Pub 1986. PMID: 3515475.
Thall PF. A theorem on regular infinitely divisible Cox processes. Stochastic Processes and Applics 16(2):205-210, 1984. e-Pub 1984.
Thall PF. Cluster shock models. J Applied Probability 18:104-111, 1981. e-Pub 1981.
Kimeldorf G, Thall PF. A joint characterization of the multinomial distribution and the Poisson process. J Applied Probability 20:202-208, 1981. e-Pub 1981.
Ammann LP, Thall PF. Count distributions, orderliness and invariance of Poisson cluster processes. J Applied Probability 16:261-273, 1979. e-Pub 1979.
Thall PF. Huber-sense robust M-estimation of a scale parameter with application to the exponential distribution. J American Statistical Assoc 74:147-152, 1979. e-Pub 1979.
Ammann LP, Thall PF. Random measures with aftereffects. Annals of Probability 6:216-230, 1978. e-Pub 1978.
Ammann LP, Thall PF. On the structure of regular infinitely divisible point processes. Stochastic Processes and Applics 6:87-94, 1977. e-Pub 1977.
Kullback S, Thall PF. An information-theoretic proof of the integral representation theorem. J. Combinatorics, Information and System Sciences 2:97-103, 1977. e-Pub 1977.
Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose selection with confirmatory treatment comparison. Biometrics.

Invited Articles

Thall PF, Garrett-Mayer E, Wages NA, Halabi S, Cheung YK. Current issues in dose-finding designs: A response to the US Food and Drug Adminstrations's oncology center of excellence project optimus. Clin Trials:17407745241234652. e-Pub 2024. PMID: 38570906.
Thall PF. Adaptive enrichment designs in clinical trials. Annual Review of Statistics and Its Application 8:393-411, 2021. e-Pub 2021.
Lin R, Thall PF, Yuan Y. BAGS: A Bayesian adaptive group sequential trial design with subgroup-specific survival comparisons. J American Statistical Association 116:322-334, 2021. e-Pub 2021.
Thall PF. Bayesian cancer clinical trial designs with subgroup-specific decisions. Contemp Clin Trials:105860, 2020. e-Pub 2020. PMID: 31678411.
Gauthier J, Yuan Y, Thall PF. Bayesian phase 1/2 trial designs and cellular immunotherapies: a practical primer. Cell and Gene Therapy Insights 5:1483-1494, 2019. e-Pub 2019.
Thall PF. Discussion of 'Optimal treatment allocations in space and time for on-line control of an emerging infectious disease' by Laber, et al. Statistical Society, Series C (Applied Statistics) 67:743-789, 2018. e-Pub 2018.
Thall PF. Discussion of "From start to finish: a framework for the production of small area official statistics" by Tzavidis, et al. J Royal Statistical Society, Series A 181:927-979, 2018. e-Pub 2018.
Müller P, Xu Y, Thall PF. Clinical trial design as a decision problem. Appl Stoch Models Bus Ind 33(3):296-301, 2017. e-Pub 2017. PMID: 29200977.
Thall, PF. Interview by EB Laber and M Davidian, in "Dynamic treatment regimes, past, present, and future: A conversation with experts.". Statistical Methods in Medical Research 26:1605-1610, 2017. e-Pub 2017.
Thall PF. Invited Discussion of "Beyond subjective and objective in statistics” by Gelman and Hennig. J Royal Statistical Society, Series A 180:1-31, 2017. e-Pub 2017.
Thall PF. Invited Discussion of "Statistical modelling of citation exchange between statistics journals" by Varin, Cattelan and Firth. J Royal Statistical Society, Series A 180:1-31, 2016. e-Pub 2016.
Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol 26(8):1621-8, 2015. e-Pub 2015. PMID: 25979922.
Thall. Discussion of Analysis of forensic DNA mixtures with artefacts by Cowell, Graversen, Lauritzen and Mortera. J Royal Statistical Society, Series C 64:1-48, 2015. e-Pub 2015.
Thall PF. Bayesian adaptive dose-finding based on efficacy and toxicity. J. Statistical Research 14:187-202, 2012. e-Pub 2012.
Thall PF. Bayesian models and decision algorithms for complex early phase clinical trials. Stat Sci 25(2):227-44, 2010. e-Pub 2010. PMID: 21318084.
Thall PF. Invited discussion of “A hybrid selection and testing procedure with curtailment for comparative clinical trials" by E. Buzaianu and P. Chen. Sequential Analysis 28:41-43, 2009. e-Pub 2009.
Thall PF, Wathen JK. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Curr Opin Oncol 20(4):407-11, 2008. e-Pub 2008. PMID: 18525336.
Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Anal 14(1):37-53, 2008. e-Pub 2008. PMID: 17763973.
Thall PF. Some geometric methods for constructing decision criteria based on two-dimensional parameters. J Stat Plan Inference 138(2):516-527, 2008. e-Pub 2008. PMID: 18617987.
Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 43(5):859-66, 2007. e-Pub 2007. PMID: 17306975.
Thall PF, Cook JD, Estey EH. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat 16(5):623-38, 2006. e-Pub 2006. PMID: 17037262.
Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer 13:251-61, 2003. e-Pub 2003. PMID: 12801254.
Thall PF. Bayesian clinical trial design in a cancer center. Chance 14:23-28, 2001. e-Pub 2001.
Msaouel P, Lee J, Thall PF. Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical Trials.

Review Articles

Thall PF. Practical Bayesian Guidelines for Small Randomized Oncology Trials. Cancers (Basel) 17(12), 2025. e-Pub 2025. PMID: 40563553.
Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clin Cancer Res 29(22):4549-4554, 2023. e-Pub 2023. PMID: 37725573.
Msaouel P, Lee J, Thall PF. Interpreting Randomized Controlled Trials. Cancers (Basel) 15(19):4674, 2023. e-Pub 2023. PMID: 37835368.
Msaouel P, Lee J, Karam JA, Thall PF. A causal framework for making individualized treatment decisions in oncology. Cancers (Basel) 14(16), 2022. e-Pub 2022. PMID: 36010916.
Msaouel P, Lee J, Thall PF. Making patient-specific treatment decisions using Prognostic Variables and Utilities of clinical outcomes. Cancers (Basel) 13(11):2741, 2021. e-Pub 2021. PMID: 34205968.
Thall PF. Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 33015521.
O'Brien S, Thall PF, Siciliano MJ. Cytogenetics of chronic myelogenous leukaemia. Baillieres Clin Haematol 10:259-76, 1997. e-Pub 1997. PMID: 9376663.
Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 14:296-303, 1996. e-Pub 1996. PMID: 8558211.
Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med 13:417-29, 1994. e-Pub 1994. PMID: 8023026.

Book Chapters

Thall PF, Lee, J. Bayesian dose-finding in two treatment cycles based on efficacy and toxicity. In: Handbook of Precision Medicine. E. Moodie, (ed), 2024.
Thall, PF. Bayesian Statistical Methods in Stem Cell Transplantation and Cellular Therapy, 39-52, 2023.
Thall PF. Bayesian Statistical Methods in Stem Cell Transplantation and Cellular Therapy. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. 1st. Elsevier, pp. 39-52, 2023.
Thall PF. Bayesian adaptive methods for clinical trials of targeted agents. In: In: Design and Analysis of Clinical Trials for Predictive Medicine: Applications in Cancer and Other Chronic Diseases. Chapman & Hall/CRC, 789-809, 2015.
Thall PF, Fox P, Wathen JK. Some caveats for outcome adaptive randomization in clinical trials. In: Modern Adaptive Randomized Clinical Trials: Statistical, Operational, and Regulatory Aspects. Taylor & Francis, 287-305, 2015.
Thall PF. SMART design, conduct, and analysis in oncology. In: Dynamic Treatment Regimes in Practice: Planning Trials and Analyzing Data for Personalized Medicine. ASA-SIAM, 2015.
Thall PF, Nguyen H, Szabo A. Adaptive decision making based on interval censored data in a clinical trial to optimize rapid treatment of stroke. In: D. Chen, J. Sun and K. Peace (eds.) Interval Censored Time-to-Event Data in Clinical Trials: New Model Developments and Computational Strategies. Chapman & Hall/CRC, 329-43, 2012.
Wathen JK, Thall PF. Application of a Bayesian doubly optimal group sequential design for clinical trials: localized surgery versus chemotherapy for non-small-cell lung cancer. In: Frontiers of Statistical Decision Making and Bayesian Analysis. In honor of James O. Berger. Springer-Verlag, 257-70, 2010.
Morita S, Thall PF. Prior effective sample size of a Bayesian model. In: Encyclopedia of Biopharmaceutical Statistics. 3rd Edition. Informa Healthcare Ltd, 1066-9, 2010.
Thall PF, Nguyen H. Covariate-adjusted adaptive dose-finding in early phase clinical trials. In: Encyclopedia of Biopharmaceutical Statistics. 3rd Edition. Informa Healthcare Ltd, 369-79, 2010.
Thall PF, Wang X. Parametric likelihoods for multiple non-fatal competing risks and death, with application cancer data. In: Design and Analysis of Clinical Trials with Time-to-Event Endpoints. Chapman & Hall / CRC Taylor & France Group, Biostatistics Series, 371-385, 2009.
Braun TM, Thall PF. Optimizing schedule of administration in phase I clinical trials. In: Encyclopedia of Clinical Trials. John Wiley & Sons, 2008.
Thall PF, Cook JD. Adaptive dose-finding based on efficacy-toxicity trade-offs. In: Encyclopedia of Biopharmaceutical Statistics. 2nd Edition, 1-5, 2006.
Thall, PF, Wang, X. Bayesian sensitivity analyses of confounded treatment effects. In: Handbook of Statistics in Clinical Oncology: Second Edition, Revised and Expanded. Chapman & Hall/CRC Taylor & Francis Group, 523-40, 2006.
Thall PF. A two-stage design for dose-finding with two cytotoxic agents in phase I trials. In: Statistical Methods for Dose Finding Experiments. John Wiley & Sons, 259-74, 2006.
Thall PF, Cook JD. Using both efficacy and toxicity for dose-finding. In: Statistical Methods for Dose Finding Experiments. John Wiley & Sons, 275-85, 2006.
Bekele BN, Thall PF. Dose-finding based on multiple ordinal toxicities. In: Statistical Methods for Dose Finding Experiments. John Wiley & Sons, 243-58, 2006.
Thall, PF, Sung, H-G, Estey, EH. Multi-course treatment strategies for clinical trials of rapidly fatal diseases (with discussion), Invited paper. In: Case Studies in Bayesian Statistics VI, Lecture Notes in Statistics 167. Springer, 33-89, 2002.
Thall, PF, Estey, EH. Graphical methods for evaluating covariate effects in the Cox model. In: Handbook of Statistics in Clinical Oncology. Marcel-Dekker, 411-432, 2001.
Millikan, R, Thall, PF. Statistical considerations in the phase II evaluation of new therapies. In: Current Clinical Urology: Bladder Cancer: Current Diagnosis and Treatment. Humana Press, 423-438, 2001.
Simon R, Thall PF. Phase II clinical trials. In: Encyclopedia of Biostatistics, Volume 4. John Wiley & Sons Ltd, 3370-3376, 1998.
Thall, PF, Simon, R. Recent developments in the design of phase II clinical trials. In: Recent Advances in the Design and Analysis of Clinical Trials. Kluwer, 49-71, 1995.

Books (edited and written)

Thall, PF. Bayesian precision medicine. Chapman & Hall/CRC Press, 2024.
Thall PF. Statistical Remedies for Medical Researchers, 2020.
Yuan Y, Nguyen HQ, Thall PF. Bayesian Designs for Phase I-II Clinical Trials. Chapman & Hall/CRC Biostatistics Series, 2016.
Thall PF. Recent Advances in Clinical Trial Design and Analysis. Kluwer Academic Publishers, 1995.

Letters to the Editor

Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL. In Reply to Krishnatry and Manjali. Int J Radiat Oncol Biol Phys 104: 468-469, 2019.
Aparicio A, Thall PF, Logothetis C. Letter to the Editor, on the paper 'Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial.' Parker, et al. The Lancet 394: 829-830, 2019.
Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL. A Phase I/II Trial of Reirradiation for Diffuse Intrinsic Pontine Giloma". International Journal of Radiation Oncology, Biology, Physics 104: 144-148, 2019.
Yan F, Thall PF, Yuan Y. Letter to the Editor, on the paper 'One-year outcomes after PCI strategies in cardiogenic shock' Thiel, et al. New England Journal of Medicine 380: 1876-1877, 2019.
Tannir N, Thall PF, Millikan R. How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shift. European Urology 62: 1020-1, 2012.
Millikan R, Logothetis C, Thall PF. Response:Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. J Natl Cancer Inst 100: 682-683, 2008.
Cheung YK, Inoue LYT, Wathen JK, Thall PF. Responses to comments on "Continuous Bayesian adaptive randomization based on event times with covariates" by Y.K. Cheung et al. Stat in Medicine 26: 3052-3054, 2006.
Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biology of Blood and Marrow Transplantation 9: 722-724, 2003.

Less

CV information above last modified August 13, 2026

Peter F. Thall

About Peter F. Thall

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Peter F. Thall

About Peter F. Thall

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson